Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Cited by 100 Publications

Nature, 2011, 471(7337):235-9

PubMed: 21390130

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062

Cell, 2014, 158(5):989-99

PubMed: 25131989

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096

Blood, 2013, 123(5):706-16

PubMed: 24319254

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543

Nat Commun, 2014, 5:3361

PubMed: 24553445

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941
EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937

Blood Cancer J, 2015, 5:e312

PubMed: 25978432
Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857

Int J Cancer, 2015, 136(11):2717-29

PubMed:

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed:

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395
Sci Signal, 2010, 3(146):ra80

PubMed: 21045206

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732

Cell Death Dis, 2013, 4:e733

PubMed: 23868066

Cell Death Dis, 2013, 4:e951

PubMed: 24309938

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394
Br J Haematol, 2015, 168(3):371-83

PubMed:

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed:

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed:

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329

J Transl Med, 2011, 9:37

PubMed: 21477288

J Biol Chem, 2015, 290(8):5028-40

PubMed:

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197
J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed:

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324
Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140

BMC Cancer, 2015, 15(1):273

PubMed: 25880212

BMC Cancer, 2014, 14(1):373

PubMed: 24886166

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006

PLoS One, 2013, 8(1):e53766

PubMed: 23320102

PLoS One, 2012, 7(9):e44265

PubMed: 22957056

PLoS One, 2012, 7(12):e52335

PubMed: 23272238

PLoS One, 2012, 7(12):e52753

PubMed: 23300762
PLoS One, 2011, 6(7):e22739

PubMed: 21818379

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901

BMC Neurosci, 2011, 12:50

PubMed: 21615950

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420
Cytometry A, 2014, 85(1):78-87

PubMed: 24038859

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed:

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389

20 Customer Reviews

Activity of vorinostat in Jurkat and Peer T-ALL cell lines in an MTT cell viability assay. Cells were treated with increasing drug concentrations for 72 h. The data are plotted as the mean % of DMSO-treated control cells against the corresponding drug concentration. The error bars are the standard error. For each drug and cell line, 3-4 independent experiments were performed with 6 replicates at each drug concentration.

Nature 2011 471, 235-9. Vorinostat (SAHA, MK0683) purchased from Selleck.

Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.

Nat Biotechnol 2011 29, 255-265. Vorinostat (SAHA, MK0683) purchased from Selleck.
Western blot analysis of histone H3 acetylation in the spleen of untreated and vorinostat-treated hNF-E2 tg mice (n = 4 of each genotype).

J Exp Med 2012 209, 35-50. Vorinostat (SAHA, MK0683) purchased from Selleck.

SAHA down-regulates c-FLIP expression and increases the sensitivity of CaP cells to undergo apoptosis in the presence of bicalutamide (A) Bar graph illustrating the sub-G0/G1 cell population in 22Rv1 (left panel) and LNCaP (right panel) cells in the absence and presence of 10μM bicalutamide, administered as a single agent or in ombination with increasing concentrations of the HDAC inhibitor, SAHA. (B) Immunoblots demonstrating the single agent activity of bicalutamide or SAHA, or effect upon their combined administration on the expression of c-FLIP and/or the processing of PARP. Equal protein loading was confirmed by GAPDH. (C) Bar graph illustrating the effect of bicalutamide and SAHA upon the induction of caspase-8 or caspase-3/7 activity in 22Rv1 cells (left panel) and LNCaP cells (right panel). (D) Immunoblots characterizing the impact of SAHA and/or bicalutamide upon the induction of PARP cleavage, in the absence or presence of the pan-caspase inhibitor, ZIETD. ZIETD was incubated with the cells for 12 h prior to the experiment. All data points shown in (A) and (C) represent the mean ± S.E.M. value, calculated from four independent experiments.

Clin Cancer Res 2012 18, 3822-33. Vorinostat (SAHA, MK0683) purchased from Selleck.
Analyses of efficacy, potency and IC50 of HDAC inhibitors point toward HDACs 1–3 as relevant candidates for beta cell protection. Ranking and raw data on ITF drugs (Table 3) and commercial HDAC inhibitors (Table 4) underlying the heat maps of Fig. 1 (A and B). The HDAC inhibitor compounds were tested using a HDAC activity kit and recombinant proteins to determine IC50 values on each individual HDAC (right part of the table). Each drug was further tested using Real-Time Cell Analysis (RTCA) to score their maximal effective concentration (ECmax) as well as the corresponding rescue percentage of cytokine treated INS-1 cells. The drugs were ranked according to % rescue. * DMSO alone controls were included in each experiment, but not shown here. The results indicate that the highest concentrations of DMSO used here (1:1,000) were slightly potentiating the proliferation of the cells. The effects observed in this group of compounds were ascribed to the DMSO.?

Diabetologia 2012 55, 2421-2431. Vorinostat (SAHA, MK0683) purchased from Selleck.

Suberoylanilide hydroxyamic acid (SAHA) preserves CFP (+) expression in mouse optic nerves (MONs) from older mice. (a) CFP (+) mitochondria were longer and thicker in MONs from 12-month-old Thy-1 CFP mice (inset; scale bar = 2 μm). Oxygen–glucose deprivation (OGD) consistently reduced CFP pixel intensity in 12-month-old MONs despite longer and brighter CFP ( +) mitochondria (yellow arrows). (b) Blockade of AMPA/kain ate receptors with NBQX (30 μM), or pan-Histone deacetylase (HDAC) inhibition with SAHA (5 μM), effectively preserved CFP pixel intensity during OGD. The preservation of CFP (+) mitochondria correlates with protection of the CAP area during OGD and profound recovery.

J Neurochem 2012 123 Suppl 2, 108-15. Vorinostat (SAHA, MK0683) purchased from Selleck.
D and E, Regression of IL-13Ra 2-negative pancreatic tumors treated with SAHA and/or IL-13-PE. Mice were treated daily with i.p. injection of SAHA (25 mg/kg) from day 4 after tumor implantation for two weeks followed by i.t. injection of IL-13-PE (100 μ g/kg) from day 5 for two weeks. F and G, Regression of IL-13Ra 2-posotive pancreatic tumors (HS766T and MIA-PaCa2) treated with SAHA and/or IL-13-PE. The schedule of treatment was similar as in panel D and E. Statistical significances are shown by *: P < 0.05,†: P < 0.001.

J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

IL-13Rα2 expression is upregulated in pancreatic tumors but not in organs of mice after treatment with HDAC inhibi tor, SAHA. A, qRT-PCR of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. Tumors were harvested next day after IL-13-PE treatment and total RNA extracted. Data shown is ratio of human IL-13Rα2/β-actin expression and multiplied by 1000 for convenience. Bars , SD of triplicate determinations. B, qRT-PCR of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Tissues were harvested at the same time point as in panel A and total RNA extracted. Data shown is ratio of mouse IL-13Rα2/β-actin expression and multiplied by 100 for convenience. C, IHC of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. D, IHC of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Liver, brain, kidney, pancreas, lung and spleen were fixed for immunostaining of mouse IL-13Rα2 as visualized by Alexa555. Nucleus was counterstained by DAPI.

J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.
Proliferation o f HT29 and HCT116 cells after 48 h of butyrate or SAHA treatment. Proliferation measurements using the xCEL Ligence RTCA DP instrument (Roche) in cells treated with increasing doses of butyrate or SAHA, compared with control medium cells (0) (*P < 0.05). The mean ?SEM of three cell culture replicates is shown.

Mol Carcinog 2012 52, 459-74. Vorinostat (SAHA, MK0683) purchased from Selleck.

SAHA induces the down-regulation of cFLIP expression and promotes TRAIL-mediated activation of a mitochondrial-operated apoptotic pathway. a BT-474 cells were treated as indicated in Fig. 1 and the cells were then harvested to analyse caspase-8, Bid, caspase-9, caspase-3 and PARP expression, using GAPDH as the protein loading control. b BT-474 cells were treated with SAHA for 8 h at the doses indicated and subsequently, the cells were harvested and the apoptosis-related proteins were analysed in western blots as described in the "Materials and Methods". The results shown are representative of at least three independent experiments

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.
Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the "Materials and methods". The results show the mean and S.E.M. of three independent experiments

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

SAHA facilitates the Itch/AIP4-independent proteasomal degradation of cFLIP proteins in breast cancer cells. a BT-474 cells were treated with SAHA (5 μM) for 8 h in the presence or absence of the proteasome inhibitors MG132 or epoxomicin (at the doses indicated), and they were then harvested and the cFLIP content was analysed in western blots. b BT-474 cells were transfected with either the siRNA oligonucleotides targeting Itch/AIP4 or the non-targeting RNA oligonucleotide (scrambled) for 48 h as described in the "Materials and Methods". Subsequently, the cells were treated with SAHA (5 μM) for 8 h and then cFLIP and Itch/AIP4 expression was analysed in immunoblots

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.
cFLIP down-regulation following SAHA treatment is responsible for the sensitization of breast cancer cells to TRAIL. a BT-474 cells were transfected with either different siRNAs directed against the cFLIP isoforms or the non-targeting RNA oligonucleotide (scrambled) as described in the "Materials and Methods". After 24 h, the cells were treated with TRAIL (500 ng/ml) for a further 15 h and apoptosis was then measured as the percentage of cells with subG1 DNA content. The results show the mean and S.E.M. of three independent experiments. To verify protein knockdown, cells were harvested 24 h after transfection and the cFLIP levels were assessed in immunoblots. b. BT-474 cells overexpressing Cflipl (pBABE-FLIPL) or control cells (pBABE) were treated with SAHA for 8 h at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some cultures for 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content and the results show the mean and range of two independent experiments. Western blots show the cFLIP levels after SAHA treatment in pBABE and pBABE-FLIPL cells.

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

Vorinostat inhibits the tumor growth. NOD ⁄ SCID-B2m^-/-mice were injected s.c. with 1×10⁶ MyLa2059 cells into both flanks. When the mice had developed established palpable tumors treatment was initiated (day 1). The mice received either vehicle (black line) or 60 mg ⁄ kg vorinostat (grey line) i.p. five days a week. In total, there were four mice in the group receiving vehicle and three mice in the group receiving vorinostat. The length and width of the tumors were measured continuously until the experiment was terminated on day 20 post treatment initiation. The tumor volume was calculated using the formula V = (a×b²)/2, where a defines the length (mm) and b the width (mm) of the tumor. The histogram shows the average tumor volume per flank ± SEM. * denotes a significant difference (P < 0.05) in the average tumor volume per flank between mice treated with vehicle and vorinostat at the given time-point both by using a one-tailed two samples test with Welch^,scorrection and a Mann-Whitney U test.

Exp Dermatol 2010 19, 1096-1102. Vorinostat (SAHA, MK0683) purchased from Selleck.
(a) Western blot of whole cell extracts demonstrates SAHA and NaB treatment result in increased levels of acetylated histone H3 compared to vehicle controls. (b) Light micrographs of HDACi/vehicle treated cultures illustrate the paucity of neurospheres in HDACi-treated cultures. (c) Quantitative analysis confirms SAHA and NaB inhibit the formation of neurospheres (diameter ≥ 50 μm) and increase the prevalence of small cell clusters (≥ 4 cell, diameter < 50 μm). (d) Flow cytometry using LIVE/DEAD cell stain confirms SAHA and NaB are minimally toxic compared to vehicle controls (n = 3). Scale bar = 100 μm.

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

(a) EdU flow cytometry of live cell-gated adult mouse NSCs demonstrates SAHA (**p < 0.01) and NaB (***p < 0.001) significantly inhibit DNA synthesis. (b) Analysis of DNA content by flow cytometry reveals significant accumulation of adult mouse NSCs in G1phase of the cell cycle following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (c) Correspondingly the proportion of cells in G2/M phase is significantly reduced following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (d) Fluorescence micrographs of HDACi/vehicle treated adult NSCs pulse-labeled with EdU for flow cytometry. Scale bar = 50 μm. Statistical comparisons performed using one-way ANOVA with post hoc Newman-Keuls multiple comparison tests.

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.
(a) Immunofluorescence labeling of NeuN, GFAP and Olig2 cell fate markers reveals reduced expression of GFAP (*p < 0.001) and Olig2 (*p < 0.05) in adult mouse NSCs treated with SAHA for 48 hours under proliferation culture conditions and then induced to differentiate for 14 days in culture (two-way ANOVA with Bonferroni post-tests). (b) Western blot of β-catenin protein in nuclear and cytoplasmic fractions of adult mouse NSCs treated with HDACi/vehicle control under proliferation culture conditions. Gapdh and lamin A/C blots are included as loading controls. (c) SAHA and NaB do not significantly alter nuclear/cytoplasmic levels of β-catenin in adult mouse NSCs. Histogram of β-catenin Western blot signal intensities normalized to loading controls (n = 4).

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

Morphological changes and histone H3 phosphorylation of HB cells treated with a combination of VX-680 and SAHA. HUH6 and HepT1 were incubated with VX-680 (6 μM) and SAHA (0.5 μM). Nuclei diameter (a) and cell diameter (b) were determined 72 h later by DAPI staining and microscopy. Data represent mean±SD of the diameters from 20 cells in each experiment. (* Two-way ANOVA, Bonferroni test, p \0.05). c Western blot analysis on HUH6 and HepT1 cells were carried out with an anti-phospho-Histone H3 (Ser 10) antibody (p-H3) 24 h after incubation with VX-680 (10 μM), SAHA (0.2 μM) or a combination of both. Controls were left untreated. Western blot analysis showed a decrease in p–H3 after treatment with VX-680 ( lane 2 ) relative to controls ( lane 1 ) and an increase when SAHA was added ( lane 3 ). For the combination of VX-680 and SAHA (lane 4 ) no p-H3 was detected.

Pediatr Surg Int 2012 28, 579-89. Vorinostat (SAHA, MK0683) purchased from Selleck.
Vorinostat promotes C2C12 differentiation.In the image, the red is the myotube indicating differentiation ,the blue is the nuclei.

Dr. Akihiko Yoshimura of Akihiko Yoshimura. Vorinostat (SAHA, MK0683) purchased from Selleck.

Western blot analysis of Acetyl-H3 and H3. 0-20μM SAHA was added.

Dr. Zhang of Tianjin Medical University. Vorinostat (SAHA, MK0683) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	Mn7QT4lv[XOnIFHzd4F6		M1rENVEhcA>?	M1nNUWROW09?	Mm\LZY51cS2KRFHDNUBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xNVIh\|ryP	MnzlNVE6PjB2OEm=
Friend leukemic cell	MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XQbFUxKM7:TR?=	MmSxO\|IhcA>?	MV7EUXNQ	M1LiWGlEPTB;MD65PUDPxE1?	MYqxNlExQTlzMx?=
K562	NYG1ZYk6U2mwYYPlJGF{e2G7		M4S3eFYhcA>?	MofzSG1UVw>?	NHHhW\|FKdmirYnn0bY9vKG:oIHj1cYFvKGirc4TvcoUh\GWjY3X0fYxie2ViKH3pfJR2emVib3[gTGRCSzFiYX7kJGhFSUN{KTD3bZRpKEmFNUCgc4YhOC5yMTFOwG0>	NX75b2VzOTJ2MUmzPFA>
HT1080	NXzo[WRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1\wVVczKGh?	M3jISmROW09?	MkfOTWM2OD1{LkSg{txO	MoPPNVIzPzBzN{W=
H1299	M37DfGtqdmG\|ZTDBd5NigQ>?		NIPy[mkzOCCvaX6=	MXvEUXNQ	NETvclZKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhUESDQzDlcpp6dWVid3n0bEBKSzVyIH;mJFAvOTl2IN88US=>	NGrkUlEyPDV{MUSyNi=>
H1299	NGjYS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4PCN\|czKGh?	NWf6dWl5TE2VTx?=	M4TMfmlEPTB;Nz6yOEDPxE1?	MlT0NVQ2OjF2MkK=
HeLa	MkC0T4lv[XOnIFHzd4F6		NUXFenEzOzBibXnu		NWTLT4lIUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgbIl{fG:wZTDk[YFk\XS7bHHz[UB4cXSqIFnDOVAhd2ZiMD6yPEDPxE1?	MnzPNVU3ODN7NEm=
LOX-IMVI	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUixOmM5PDhiaB?=		MYPJR\|UxRTFwMzFOwG0>	NXPVc41xOTV5MUW0O\|A>
NCI-H226	MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1\0[\|Q5KGh?		M2O3fGlEPTB;Mj62JO69VQ>?	NWDMe\|NvOTV5MUW0O\|A>
RXF-631L	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH\TZYs1QCCq		NEjY[GtKSzVyPUKg{txO	MXyxOVcyPTR5MB?=
SNB-78	M1jjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlizOFghcA>?		MmTHTWM2OD1zNjFOwG0>	MVOxOVcyPTR5MB?=
St-4	M1y2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2TZUlQ5KGh?		NGLOXXBKSzVyPUWuNkDPxE1?	NYX1fYVnOTV5MUW0O\|A>
ARP1	M3rl[GZ2dmO2aX;uJGF{e2G7	NIO2O3kzKM7:TR?=	M2fqVVYhcA>?		MWDJcoR2[3Srb36gc4YhWDJzV1HGNUBo\W6nIHX4dJJme3Orb36=	MYKxOFc{PDhyNh?=
CEM	NGPjNFZMcW6jc3WgRZN{[Xl?		MYexJIg>	NXvRZ2pyTE2VTx?=	NXztbndyUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM{KM7:TR?=	NHvYZpoyPjR{MEC2OC=>
HCT15	M1;ITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH\DS3E1QCCq		M3\WTWdKPTB;MD64NkDPxE1?	M{DVRlE3PzJ\|MkK3
NCI-H23	MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUe0PEBp		MWjHTVUxRTBwOUKg{txO	M{C3NFE3PzJ\|MkK3
GM15850	M1freGtqdmG\|ZTDBd5NigQ>?	M2H6TFIvPSEQvF2=	NIXZW2w6PiCq	NYTz[HJoTE2VTx?=	M4eyXGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIx6e2mwZTCxOEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	M2e2ZVE3QTJzM{[3
GM15850	NVrh[oZIU2mwYYPlJGF{e2G7	M32xWFIvPSEQvF2=	NULQZ5duQTZiaB?=	NIXsTWpFVVOR	NFrTWplKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	M4H0[FE3QTJzM{[3
GM15850	M{[zeGtqdmG\|ZTDBd5NigQ>?	MVSyMlUh\|ryP	NX7GcY05QTZiaB?=	MkLZSG1UVw>?	NGOxNndKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVIh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NWD5[odvOTZ7MkGzOlc>
GM15850	NVG3fYNVU2mwYYPlJGF{e2G7	M1PwPFIvPSEQvF2=	NEi3NI06PiCq	MY\EUXNQ	Mor6TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgcJl{cW6nIEmgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	MXixOlkzOTN4Nx?=
GM15850	NHvVO29McW6jc3WgRZN{[Xl?	MoLKNk42KM7:TR?=	MlzzPVYhcA>?	MoH4SG1UVw>?	NWiyelNjUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFgh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M3HSNlE3QTJzM{[3
GM15850	MUfLbY5ie2ViQYPzZZk>	NX3FPWR{Oi53IN88US=>	NWDWboxEQTZiaB?=	NG\qNWdFVVOR	NUXSTYFnUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MnPmNVY6OjF\|Nke=
U937	M4nHdmZ2dmO2aX;uJGF{e2G7	MnnlOUDPxE1?	NW\jZWs{OjRiaB?=	M17nXmROW09?	NXrDdnRtS2WubDDjfYNt\SCjcoLld5Qh[nliYXPjeY12dGG2aX;uJIF1KFNxR{KvUUBxcGG\|ZR?=	M4[1fVE4ODB2N{G4
H661	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYTHSmR{PDhiaB?=		MXLJR\|UxRTFizszN	MkHGNVcyPTdyMEm=
U937	M37aOmZ2dmO2aX;uJGF{e2G7	M1[yTlUh\|ryP	MY[yOEBp	NVXLfI1uTE2VTx?=	M123NGlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36=	NGDDPVcyPzR2N{e1NC=>
U937	MUXGeY5kfGmxbjDBd5NigQ>?	NFuxSIQyKM7:TR?=	NXX5UJFqOjRiaB?=	NFrYRlRFVVOR	M{fUV2Vn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u	MWGxO\|Q1Pzd3MB?=
RAW264.7	MUPGeY5kfGmxbjDBd5NigQ>?	NFnvVIwyOCEQvF2=	M3GyXlI1cA>?	MYL3ZZRmeg>?	NIKxNVJKdmirYnn0bY9vKG:oIFzQV{1{fGmvdXzheIVlKFSQRnHsdIhiKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvPzZizszN	NFTBSIcyPzR5N{WxPC=>
RAW264.7	MWLGeY5kfGmxbjDBd5NigQ>?	NWjCb2JROTBizszN	M{PQb\|I1cA>?	NEL5O\|Z4[XSnch?=	MmH2TY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBPVyCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAyNjh6IN88US=>	MnvSNVc1Pzd3MUi=
SC9	MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{DoR\|Q5KGh?		MoS5TWM2OD1yLk[wOkDPxE1?	MUixO\|UxPzJzOR?=
ST14A	NWnJNI5zTnWwY4Tpc44hSXO\|YYm=	M1TJdFUhdk1?	MXO3NkBp		M2rvWGlv[3KnYYPlJIlvKFKHU2SvUnJUTiCvUl7BJIV5eHKnc4Ppc44>	M{PtSlE4PTZ3OUmz
ST14A	Mn\3SpVv[3Srb36gRZN{[Xl?	Mnq5OUBvVQ>?	M1K2RVczKGh?		MW\JcoNz\WG\|ZTDpckBGOkZzIH3SUmEh\XiycnXzd4lwdg>?	NWXFNVFTOTd3NkW5PVM>
PANC1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXixJO69VQ>?			NELqNHRKSzVyPUCuOFUh\|ryP	NIrKOmQyPzV6OEe0OC=>
PANC1	MX;GeY5kfGmxbjDBd5NigQ>?	MV2xJO69VQ>?	MlL5NlQhcA>?		MonqTY5kemWjc3WgbY4heDJzV1HGNU9EUVBzIHflcoUh\XiycnXzd4lwdg>?	NEPoWGIyPzV6OEe0OC=>
PANC1	MYHGeY5kfGmxbjDBd5NigQ>?	NWS1cWd{OSEQvF2=	M4jpTVI1KGh?		NGjnfHhKdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW\|c3nvci=>	NYDWVmRyOTd3OEi3OFQ>
PT45	Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1WxTWlEPTB;NDFOwG0>	MXWxO\|U5QDd2NB?=
ACHN	NXu0[JdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkfQNlEhcA>?		M1fMPGdKPTB;MD62OUDPxE1?	NFXZVmMyPzZ4Mk[wOi=>
PC3	M1O4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEH2VlczOSCq		MUXHTVUxRTBwN{Gg{txO	M2LDTFE4PjZ{NkC2
A431	NFLyboVEgXSxdH;4bYMhSXO\|YYm=		NW\jeJZlPzJiaB?=		M1TlR2lEPTB;ND6yJO69VQ>?	NHTKUWcyPzZ7MUe2Ny=>
Cal27	M2fpRWN6fG:2b4jpZ{BCe3OjeR?=		MkfUO\|IhcA>?		M4jmfGlEPTB;Mz6yJO69VQ>?	NIW4cXQyPzZ7MUe2Ny=>
CCRF-CEM	NV7keFYyS3m2b4TvfIlkKEG\|c3H5		NUDSe3gxPzJiaB?=		MX;JR\|UxRTBwODFOwG0>	NELDd28yPzZ7MUe2Ny=>
EOL1	NHrjNlhEgXSxdH;4bYMhSXO\|YYm=		MVG3NkBp		NFyyS5FKSzVyPUGg{txO	NWrSOlBLOTd4OUG3OlM>
Hec-1-A	M{H6fmN6fG:2b4jpZ{BCe3OjeR?=		NHnFT3Q4OiCq		MXPJR\|UxRTFizszN	NITKU\|cyPzZ7MUe2Ny=>
HeLa	MX3LbY5ie2ViQYPzZZk>	MYOxNEDPxE1?	MkjSN\|AhdWmw	NUfidIdQTE2VTx?=	NYqyRlIxUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBJTEGFMTD3bZRpKEmFNUCgc4YhOC5yMjFOwG0>	M4DjUFE4PjlzN{[z
RKOp21	MXPDfZRwfG:6aXOgRZN{[Xl?		M4jhOFczKGh?		MYHJR\|UxRTFwN{[g{txO	M3nqR\|E4PjlzN{[z
Saos2	MVvDfZRwfG:6aXOgRZN{[Xl?		NYO0XFlJPzJiaB?=		M4nKV2lEPTB;Mj6zJO69VQ>?	NXz0d3VIOTd4OUG3OlM>
SK-OV-3	NWThdVdKS3m2b4TvfIlkKEG\|c3H5		MYK3NkBp		MVPJR\|UxRTJwMjFOwG0>	NIXxeIIyPzZ7MUe2Ny=>
U87MG	NVz6cJBxS3m2b4TvfIlkKEG\|c3H5		MX23NkBp		NXfRfnBQUUN3ME2xNUDPxE1?	NH\kU24yPzZ7MUe2Ny=>
NUGC3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1exT\|Uh\|ryP	M4DKe\|I1KGh?		M1zldGdKPTB;Mj63PUDPxE1?	MnnhNVc6ODR6NEO=
CCD1059SK	M4PwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nLVGlEPTB;NEOuOUDPxE1?	Mn7qNVgzPDd3NUS=
HepG2	M2[5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\XTWM2OD1yLkCwNFYh\|ryP	MVixPFI1PzV3NB?=
HT1080	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETNWIVKSzVyPUCuNFAzPCEQvF2=	NXrESFBbOTh{NEe1OVQ>
SKBR3	NYK4fopKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXQRXdKSzVyPUCuPEDPxE1?	NY\zTVdLOTh{NEe1OVQ>
SNB78	NFXT[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7FR\|UxRTF4IN88US=>	Ml\4NVgzPDd3NUS=
SQ20B	MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlH0TWM2OD1\|IN88US=>	M16yeFE5OjR5NUW0
St4	NFqy[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDldIVGSzVyPUWuNkDPxE1?	M{ize\|E5OjR5NUW0
MCF7	NVrXVWVrTnWwY4Tpc44hSXO\|YYm=	MYSxNEDPxE1?	MYS4JIg>	NVTMOHdzTE2VTx?=	NILkbYVKdmS3Y4Tpc44hd2ZidIXieYxqdiCqeYDldoFk\XS7bHH0bY9v	MnPpNVgzPjl{Mk[=
HEK293	M37oRmtqdmG\|ZTDBd5NigQ>?		M1XjPFEhcA>?	NHvCfHJFVVOR	MnfVTY5pcWKrdHnvckBw\iCKRFHDNUB4cXSqIFnDOVAhd2ZiMD6wN{DPxE1?	NEP0eVgyQDNyOEW2Ny=>
HEK293	NEjMR4xMcW6jc3WgRZN{[Xl?		NUfyZ4tTOSCq	M4HlSmROW09?	Mm\VTY5pcWKrdHnvckBw\iCKRFHDN{B4cXSqIFnDOVAhd2ZiMD6wOVch\|ryP	MXqxPFMxQDV4Mx?=
G401	MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXTpN4dnPzJiaB?=	NGe0bWdFVVOR	NF\OeXNKSzVyPUGg{txO	NHT1bW4yQDN5MEO3Ny=>
HeLa	NIryelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoLNO\|IhcA>?	NYnMfZBETE2VTx?=	MlfyTWM2OD1yLkS2JO69VQ>?	NFm0cJAyQDN5MEO3Ny=>
Human renal epithelial cell	MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4XkfVczKGh?	MYXEUXNQ	M4LsNmlEPTB;MUSg{txO	Mo\UNVg{PzB\|N{O=
U937	M13F[WZ2dmO2aX;uJGF{e2G7	MmD3OUDPxE1?	NIXuTZUzPCCq		M1XDVWlv\HWldHnvckBw\iCqaYP0c45mKEh2IHj5dIVz[WOndInsZZRqd25?	NYDTfIVJOTh\|OEGyN\|g>
U937	NVHXdphiTnWwY4Tpc44hSXO\|YYm=	NXi2SFFRPSEQvF2=	MWiyOEBp		Mnu4TY5lfWO2aX;uJI9nKGGucHjhJJR2[nWuaX6gbJlx\XKjY3X0fYxifGmxbh?=	MorKNVg{QDF{M{i=
U937	MoDuSpVv[3Srb36gRZN{[Xl?	MnHnOUDPxE1?	NUe0cIVPOjRiaB?=		NWnYPHcyUW6mdXP0bY9vKG:oIICyNUBmgHC{ZYPzbY9v	MlnONVg{QDF{M{i=
U937	NHrz[mxHfW6ldHnvckBCe3OjeR?=	M3jKcFUh\|ryP	M{LGRlI1KGh?		NH7PVoZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|	M{TZO\|E5OzhzMkO4
U937	NFvrVo5HfW6ldHnvckBCe3OjeR?=	M3XsTVUh\|ryP	NI\RfpUzPCCq		Mmj5TY5lfWO2aX;uJI9nKGe{YX71cI9kgXSrYzDkbYZn\XKnboTpZZRqd25?	M{jjV\|E5OzhzMkO4
U937	MY\LbY5ie2ViQYPzZZk>	MYq1JO69VQ>?	NXfP[ZAyOjRiaB?=		MmT3TY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMR?=	Mo\qNVg{QDF{M{i=
U937	Ml7KT4lv[XOnIFHzd4F6	M1HGNlUh\|ryP	M3;hN\|I1KGh?		MWrJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN2	M4\vSlE5OzhzMkO4
HEK-TE	NFnVepVHfW6ldHnvckBCe3OjeR?=	MonOOUDPxE1?	NF\MRWc3cA>?	Mk\ESG1UVw>?	M1fTfWlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36=	MUmxPFQ{PDF2NB?=
HPDE6c7	NHzsUlBEgXSxdH;4bYMhSXO\|YYm=	NETYO\|U2OCEQvF2=	NV3OVVdUPzJiaB?=	MYLEUXNQ	M3\mO2lEPTB;MT6zJO69VQ>?	NHP6Om8yQDR7NES2Ny=>
Human microvascular epithelial cell	NHP5[3VEgXSxdH;4bYMhSXO\|YYm=	NVvRN4RmPTBizszN	MVW3NkBp	MmnZSG1UVw>?	MljJTWM2OD1zLkOg{txO	NGj0SVEyQDR7NES2Ny=>
Hup T3	M1fJSWN6fG:2b4jpZ{BCe3OjeR?=	MnG3OVAh\|ryP	M1X0TVczcA>?	M3LyemROW09?	MnjPTWM2OD1yLkig{txO	NGLHUI4yQDR7NES2Ny=>
Mia Paca2	M2fYW2N6fG:2b4jpZ{BCe3OjeR?=	NHzQbIg2OCEQvF2=	NVXvU5F{PzKq	NFjNXXJFVVOR	MX7JR\|UxRTFwMTFOwG0>	NXnUTmxwOTh2OUS0OlM>
Panc 04.03	Mn;yR5l1d3SxeHnjJGF{e2G7	M1rG[\|UxKM7:TR?=	NWX6PXBQPzKq	Mnv3SG1UVw>?	MXLJR\|UxRTFwMjFOwG0>	MmXINVg1QTR2NkO=
SU 86.86	MorSR5l1d3SxeHnjJGF{e2G7	M3f3T\|UxKM7:TR?=	NUO0[oRvPzKq	NVzwXW9sTE2VTx?=	NIKyR\|lKSzVyPUGuN{DPxE1?	NEjCOlcyQDR7NES2Ny=>
HEK293	MlPvT4lv[XOnIFHzd4F6		MVWzJIg>		MYTJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nqd25id3n0bEBKSzVyIH;mJFAvODF7IN88US=>	NUDJTmtnOTh3NUi2Olk>
HeLa	NG\Pb2dMcW6jc3WgRZN{[Xl?		Ml7MNkBp		MVHJcohq[mm2aX;uJI9nKG63Y3zlZZIhUESDQzD3bZRpKEmFNUCgc4YhOC5yOEOg{txO	M2WyR\|E5PTV6Nk[5
RAW264.7	NHLJeppHfW6ldHnvckBCe3OjeR?=	NH:xTmwzKM7:TR?=	NVvvdZhnOy53IHi=	NG[3b5lFVVOR	NUTXW3BmSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJIlv\mWldHXkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>?	NHuwRZoyQDZ2NEm2PS=>
NB4			NVrFOJV7PDiq	NGHjfopFVVOR	M2X3S2lEPTB;MD62JO69VQ>?	NHL6SGgyQDd{M{O0PS=>
HEK293	Mlr2SpVv[3Srb36gRZN{[Xl?	MoXGNVAh\|ryP	Mo\RNlQhcA>?	M4rldmROW09?	MU\BZ5RqfmG2aX;uJI9nKG2xdYPlJHdvfDOjIIPp[45idGmwZzDlfJBz\XO\|ZXS=	Mn\KNVkxOjJ4N{W=
HCT116	NVvaUVFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWi3Nog>	MoPZSG1UVw>?	MoXETWM2OD1yLkOxJO69VQ>?	MorFNVkxQDR{OUS=
HeLa	M4q3eGtqdmG\|ZTDBd5NigQ>?	NILncZAzKM7:TR?=	M2HBVVMxKG2rbh?=	MnjnSG1UVw>?	MXPJcohq[mm2aX;uJI9nKEiGQVOyJIlvKGi3bXHuJGhmVGFiY3XscJMhf2m2aDDJR\|UxKG:oIECuNUDPxE1?	MnS0NVkxQDR{OUS=
IGROV1	NXjFNpV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWi3NkBp	M2HaXWROW09?	MULJR\|UxRTJwMjFOwG0>	M2fJV\|E6ODh2Mkm0
IGROV1	MmixT4lv[XOnIFHzd4F6	MlPZOUDPxE1?	MoXGNlQhcA>?	MXnEUXNQ	Mm\jTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KHB3MzDhZ4V1gWyjdHnvci=>	NVzHdYtjOTlyOESyPVQ>
IGROV1	NFGzUZBMcW6jc3WgRZN{[Xl?	MVyxNEDPxE1?	NEjneZE1KGh?	NHm2WXZFVVOR	NXTwfZRnUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmVvSESgZYNmfHmuYYTpc44>	MUWxPVA5PDJ7NB?=
IGROV1	MUfLbY5ie2ViQYPzZZk>	NGX5S3AyOCEQvF2=	M1T2OFQhcA>?	NUXld4kxTE2VTx?=	M1XBTmlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiYXzwbIEufHWkdXzpckBi[2W2eXzheIlwdg>?	MmX2NVkxQDR{OUS=
T24	MUTLbY5ie2ViQYPzZZk>		MXSzJIg>		NVLPPHZiUW6mdXP0bY9vKG:oIHjpd5RwdmViSEOgZYNmfHmuYYTpc44hf2m2aDDFR\|UxKG:oIECuNVIh\|ryP	NXX2OHlQOTlyOESzPVU>
T24	M{D4cWtqdmG\|ZTDBd5NigQ>?		MUSzJIg>		NIn4TpVKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBi[2W2eXzheIlwdiC5aYToJGVEPTBib3[gNE4zPSEQvF2=	M{\zUlE6ODh2M{m1
HeLa	MofCT4lv[XOnIFHzd4F6		MnGyNVUhdWmw	M1j6OWROW09?	MWHJcohq[mm2aX;uJI9nKEiGQVO2JIZzd21iboXjcIVieiCneITyZYN1KHerdHigTWM2OCCxZjCwMlA5PTVizszN	NG\WOIQyQTB7M{i4OC=>
HeLa	NVPrWFdsU2mwYYPlJGF{e2G7		M3q5XlE2KG2rbh?=	Ml7iSG1UVw>?	NEG5SlVKdmirYnn0bY9vKG:oIFjERWM5KG[{b32gcpVkdGWjcjDlfJRz[WO2IIfpeIghUUN3MDDv[kAyNjh4IN88US=>	MoLtNVkxQTN6OES=
NCI-H69	MUnDfZRwfG:6aXOgRZN{[Xl?		NUXVNmJlPzJiaB?=	MoX3SG1UVw>?	NHrTVINKSzVyPUKuNFYh\|ryP	MmnyNVkxQTN6OES=
SKMES1	M1GyUmN6fG:2b4jpZ{BCe3OjeR?=		MnL1O\|IhcA>?	MUXEUXNQ	NXXvXXVQUUN3ME2yMlQzKM7:TR?=	NYLYOnpxOTlyOUO4PFQ>
S2	NIfFXmxMcW6jc3WgRZN{[Xl?	Mlf1NE4yNTFyIN88US=>	M4fEN\|EhcA>?		MYrJcohq[mm2aX;uJI9nKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDISGFEOSCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODV7IN88US=>	MXqxPVMyPzR3MB?=
SHSY5Y	NIDGUVFMcW6jc3WgRZN{[Xl?	MmrkNVAh\|ryP	MXK0PEBp	NH\PSI9FVVOR	NIfufFFKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOUDPxE1?	MmOxNVk{PDRzN{W=
SHSY5Y	NX\vRYxVS3m2b4TvfIlkKEG\|c3H5	MmTPNVAh\|ryP	Mn7GOFghcA>?	M4HBemROW09?	NIO3c2tKSzVyPUKg{txO	NFvNUZoyQTN2NEG3OS=>
DMS114	NEG3UZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MY[0PEBp		NVm0XG5NT0l3ME2yMlkh\|ryP	NWXQNWh4OTl2MUmyNFU>
HBC5	NV:2OIdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYW0PEBp		MUnHTVUxRTF5IN88US=>	M1HKRlE6PDF7MkC1
SNB78	NYjUeXp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MonTOFghcA>?		NFTLR2JIUTVyPUG2JO69VQ>?	NXHnc3hZOTl2MUmyNFU>
HeLa	MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mo\xO\|IhcA>?	M33mTWROW09?	M4\JcWlEPTB;MD60OkDPxE1?	MkSwNVk1PDF6NE[=
BHK	NVvVTVdFU2mwYYPlJGF{e2G7	NGPQTZg2KM7:TR?=	NGm0RY4zPCCq	MXPEUXNQ	NVuwdoprUW6qaXLpeIlwdiCxZjDISGFEPyCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4heGyjc33hJI1mdWK{YX7lJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5?	NXPtbms1OTl7Nk[3PFk>
CFBE41o-	MmfzT4lv[XOnIFHzd4F6	M2nmWFUh\|ryP	MVi4JIg>	M3:4fWROW09?	M2TLUGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqeYDldoFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEO=	MkPtNVk6PjZ5OEm=
CFBE41o-	Mmr2T4lv[XOnIFHzd4F6	MlXsOUDPxE1?	NFjFd\|M1KGh?	M{KwUGROW09?	NXrPVVBGUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGyndnXs	M3[xeFE6QTZ4N{i5
CFBE41o-	MY\LbY5ie2ViQYPzZZk>	NYOzVIF7OSEQvF2=	M3jDelEhcA>?	MoG3SG1UVw>?	M2T0bmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDDSnRTKHC{b4TlbY4hdGW4ZXy=	NUC0fXJYOTl7Nk[3PFk>
Primary bronchial epithelial cell	MY\LbY5ie2ViQYPzZZk>	Ml;JNUDPxE1?	NVzUcZpJOjRiaB?=	M4i5c2ROW09?	MXfJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBieGmlYXygd5Vz\mGlZTDsc4NidGm8YYTpc44>	Ml6wNVk6PjZ5OEm=
CFBE41o-	MlGzT4lv[XOnIFHzd4F6	MmHSNUDPxE1?	MnXaOUBl[Xm\|	NXXXPVJxTE2VTx?=	NELubpRKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn6ZZRqd25ib3[gSoRmdHSjNUC4JGNHXFJicILveIVqdg>?	NXf5PVNvOTl7Nk[3PFk>
CFBE41o-	MWnLbY5ie2ViQYPzZZk>	NXLvNYxqOSEQvF2=	MoLXNlQhcA>?	NHHDZ2xFVVOR	NFz3SGFKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5idILh[oZq[2urbne=	NYTJ[nZTOTl7Nk[3PFk>
CFBE41o-	NXTtU5llU2mwYYPlJGF{e2G7	NGnSVWI2KM7:TR?=	MX6yOEBp	MXLEUXNQ	NFTIfoRKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJJifGVib3[gcYF1fXKjdHnvckBw\iCFRmTSJJBzd3SnaX6geI8hcXS\|IHfsfYNw\m:{bR?=	MmTLNVk6PjZ5OEm=
CFBE41o-	NUTWN\|RqU2mwYYPlJGF{e2G7	MVq1JO69VQ>?	M2\tdVI1KGh?	MnWzSG1UVw>?	M1zVXGlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gd5Ri[mmuaYT5JI9nKE[mZXz0ZVUxQCCFRmTSJJBzd3SnaX6=	M3\NTlE6QTZ4N{i5
CFBE41o-	MmjpT4lv[XOnIFHzd4F6	MYm1JO69VQ>?	NWrKbmo3OjRiaB?=	NILsXnhFVVOR	MkjhTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyClb4Ly[YN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiC2cnHm[olkc2mwZzD0c{Bk\WyuIIP1doZi[2ViYYOg[4x6[2:ob4Lt	NUDVbo93OTl7Nk[3PFk>
Primary bronchial epithelial cell	Ml7DT4lv[XOnIFHzd4F6	Mn7rOUDPxE1?	Mm\2NlQhcA>?	M124cWROW09?	NXX2Z2NqUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	MVmxPVk3Pjd6OR?=
Primary bronchial epithelial cell	NV73NGpnU2mwYYPlJGF{e2G7	NVTqN5JNOSEQvF2=	NFHLW5g6PiCq	M4rNPGROW09?	MXzJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIPoc5J1KGOrcnP1bZQh[3W{cnXueJM>	NVW0eJdzOTl7Nk[3PFk>
BxPC3	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVW3NkBp		NH\te4lKSzVyPUKuO{DPxE1?	MXmyNFE1Ozd5OB?=
CAL27	NELyZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnGxO\|IhcA>?		NYe2eVRDUUN3ME2zMlczKM7:TR?=	NX3hSndWOjBzNEO3O\|g>
Capan1	MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXTUVGl3PzJiaB?=		M3PjPGlEPTB;Nz6zJO69VQ>?	MnzRNlAyPDN5N{i=
HCC827	NFWwPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGD4OmU4OiCq		NV\NWYpoUUN3ME2xMlgh\|ryP	MXuyNFE1Ozd5OB?=
LNCAP	NWS2V4dIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2TvblczKGh?		MXHJR\|UxRTBwNUig{txO	NFO3SmEzODF2M{e3PC=>
NCI-H2122	NHXXOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{fLfFczKGh?		NF3uOoVKSzVyPUeuOUDPxE1?	NXHSTZZHOjBzNEO3O\|g>
NCI-H358	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmHJO\|IhcA>?		M3\DZ2lEPTB;Mj61JO69VQ>?	M{jZO\|IxOTR\|N{e4
SCC15	M{PuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIGxfHY4OiCq		M3qyVGlEPTB;Mj60PUDPxE1?	MVyyNFE1Ozd5OB?=
SCC25	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4CzclczKGh?		NYDIdIJwUUN3ME2xMlk{KM7:TR?=	NHy4O4QzODF2M{e3PC=>
SKHEP1	MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVzKUYd2PzJiaB?=		M2LzTmlEPTB;Mz60OkDPxE1?	MkPyNlAyPDN5N{i=
BJ	NUGyVJVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\TWldtOTByIN88US=>	M{XlNlQ5KGh?	MWrEUXNQ	M4npOGdzd3e2aDDpcohq[mm2aX;uJIF1KDBwMEWgeI8hOTByIIXN	MoDpNlAyPDN6NEC=
MUF	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTCbmdJOTByIN88US=>	MonPOFghcA>?	MWPEUXNQ	NX7relVRT3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6wOUB1dyBzMECgeW0>	MnGwNlAyPDN6NEC=
Caco-2	NUXWUW4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TVNVExOCEQvF2=	M{jE[VQ5cA>?	NFntVXlFVVOR	M1jQWmlEPTB;OD6xJO69VQ>?	M2C0Z\|IxOTR\|OESw
Caco-2	M1Tj[mtqdmG\|ZTDBd5NigQ>?	M3TRNFUh\|ryP	NVXubIRPPCCq	NFHFeFFFVVOR	MUPJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;uJGlEPTBib3[gNE4xOzdizszN	NU\Td4NqOjBzNEO4OFA>
Caco-2	NXnvVYpbU2mwYYPlJGF{e2G7	NXT1dXNSOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	NV[ybHBJPCCq	M4XNeGROW09?	MULFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzFid3n0bEBKSzVyIH;mJFAvOTF7IN88US=>	M2LNTlIxOTR\|OESw
Caco-2	NXqwZoVuU2mwYYPlJGF{e2G7	MkjPNE4{OTZibl2geI8hOzFwNjFOwG0>	NITlfFc1KGh?	NF\pXXBFVVOR	NHeyU5lGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Oge4l1cCCLQ{WwJI9nKDBwMUS3JO69VQ>?	NH7yN\|QzODF2M{i0NC=>
Caco-2	MlvTT4lv[XOnIFHzd4F6	NUPjNJJUPi5\|MjDuUUB1dyB4M{Kg{txO	NXuxPIFHPCCq	MUHEUXNQ	M1nDNWV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNTD3bZRpKEmFNUCgc4YhOTJwNjFOwG0>	M4O3NFIxOTR\|OESw
Caco-2	NV\IO3llU2mwYYPlJGF{e2G7	MX:2MlMzKG6PIITvJFY{OiEQvF2=	MmDZOEBp	M1;5R2ROW09?	NXn5WnJnTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO3JJdqfGhiSVO1NEBw\iB2MTFOwG0>	MkTMNlAyPDN6NEC=
Caco-2	NVj6b4xQU2mwYYPlJGF{e2G7	MnTDNE4{OTZibl2geI8hOzFwNjFOwG0>	NF\hRo41KGh?	NIPOd2lFVVOR	NX2zZnZyTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO2	NH\HU5EzODF2M{i0NC=>
HepG2	MonQT4lv[XOnIFHzd4F6	NGi0[WM2KM7:TR?=	NIfPOIw3cA>?	NWDrUVRETE2VTx?=	MWfJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;u	NHnpPGozODF2M{i0NC=>
HepG2	NX3kW28xU2mwYYPlJGF{e2G7	M1q4ZVUh\|ryP	M1u5SlZp	Ml3wSG1UVw>?	NIGyXFdKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIh6eGW{YXPleJlt[XSrb36=	MVOyNFE1Ozh2MB?=
HepG2	NHv3e3VMcW6jc3WgRZN{[Xl?	M13XfVUh\|ryP	NYnmV21uPmh?	NVfD[HNxTE2VTx?=	Mlz6TY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbh?=	NIrlN2UzODF2M{i0NC=>
HepG2	MnPmT4lv[XOnIFHzd4F6	NFrHU4Q2KM7:TR?=	Ml;ROog>	NX\6cG9sTE2VTx?=	M{PYd2lv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJGg{N0h2IHjpd5RwdmViYXPleJlt[XSrb36=	M1XCTFIxOTR\|OESw
COLO205	MXjLbY5ie2ViQYPzZZk>	MUexNEDPxE1?	NFTKO\|gzPCCq	MlSxSG1UVw>?	NHrqd5VKdmirYnn0bY9vKG:oIFjERWMyKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{KGGlZYT5cIF1cW:wIIfpeIghUUN3MDDv[kAzNjJizszN	NX[0VpMxOjB2NUGzO\|g>
SCC4	NGTsNolMcW6jc3WgRZN{[Xl?	M2eyZVEh\|ryP	MWKyOIg>		MV;Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5idIXieYxqdiCjY3X0fYxifGmxbh?=	M1vDfVIxPDV{MkK1
SCC4	MnfKT4lv[XOnIFHzd4F6	NGLnd5cyKM7:TR?=	NWD3UlFsOjSq		NEfOdHBKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDhZ4V1gWyjdHnvci=>	M1rmUVIxPDV{MkK1
SCC4	NWDDW5BZTnWwY4Tpc44hSXO\|YYm=	MVmxJO69VQ>?	MW[1JI1qdg>?		NIXHNJZC\2:waYP0JIFkfGm4aYT5JIF1KF[GUjDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiQ2nQNlQh\2WwZTDlfJBz\XO\|aX;u	NWDRcYZUOjB2NUKyNlU>
NB4	NF\Jb2ZHfW6ldHnvckBCe3OjeR?=	NIL4XG82KM7:TR?=	MoKzNlQhcA>?	NWXVfYRtTE2VTx?=	NF7mcotE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44h[XRicILlMWcyKHCqYYPl	NGq5WW0zODR7MUS0NC=>
NB4	M1vZPWtqdmG\|ZTDBd5NigQ>?	MWe1JO69VQ>?	MWqyOEBp	M2\3PWROW09?	NWDLfVluUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIFk\XS7bHH0[UB1fWK3bHnuJIxmfmWu	NHvqeWozODR7MUS0NC=>
NB4	NH\UXINHfW6ldHnvckBCe3OjeR?=	MUW1JO69VQ>?	NWKwXXpmOjRiaB?=	MU\EUXNQ	NVzEfZIzUW6mdXP0bY9vKG:oIICyNXdCTjFxQ1nQNUBmgHC{ZYPzbY9v	NYCw[XI3OjB2OUG0OFA>
NB4	MYrLbY5ie2ViQYPzZZk>	M3e5cFUh\|ryP	Ml:wNlQhcA>?	MWnEUXNQ	NUXON\|JtUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMh[WOndInsZZRqd25?	NIDKPG8zODR7MUS0NC=>
NUGC3	M3XnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DVT2dKPTB;Mj65OEDPxE1?	NWDDZoZJOjB6NUC5O\|E>
A549	M{\iO2Z2dmO2aX;uJGF{e2G7	MoXGOUDPxE1?	MoLiN{Bp	MUPEUXNQ	NGHkbYVKdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iTFOzTWk>	M{KzN\|IxQDV3MkC4
HUT78	NXfNdZJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoHtO\|IhcA>?	NY\rV3c3TE2VTx?=	MofVS2k2OD1yLkOg{txO	NGfSVVQzODh6NEKwPC=>
U937	NF3ZR\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVW3UnNvPzJiaB?=	NYDjNmVZTE2VTx?=	NI\kVoxIUTVyPUCuN\|kh\|ryP	Ml;XNlA5QDR{MEi=
A431	Moe0R5l1d3SxeHnjJGF{e2G7		Mn;mO\|IhcA>?		M4PNbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiC5aYToJGlEPTBib3[gOE4zKM7:TR?=	NVP1V3hDOjFyOEC2Nlk>
A549	NGHxdGdEgXSxdH;4bYMhSXO\|YYm=		MXS3NkBp		NU\v[FgyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjhizszN	MlHRNlExQDB4Mkm=
CAL27	M{TlW2N6fG:2b4jpZ{BCe3OjeR?=		MXO3NkBp		M3rhZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNCVDJ5IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGVITlJid3n0bEBKSzVyIH;mJFMvOiEQvF2=	MmjsNlExQDB4Mkm=
HeLa	MkiyR5l1d3SxeHnjJGF{e2G7		NVW4dFEyPzJiaB?=		MoK5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlUh\|ryP	MVeyNVA5ODZ{OR?=
Sf21	M37mUmtqdmG\|ZTDBd5NigQ>?		MWmzJIg>		M1nte2lvcGmkaYTpc44hd2ZiRnzh[{B1[WepZXSgbJVu[W5icnXjc41jcW6jboSgTGRCSzhiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyNjJizszN	Mmf5NlExQDB4Mkm=
SKBR3	MlHsR5l1d3SxeHnjJGF{e2G7		NFzle4Y4OiCq		MkfWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tDWjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk43KM7:TR?=	NWGxUZVSOjFyOEC2Nlk>
SKOV3	MljrR5l1d3SxeHnjJGF{e2G7		MlP3O\|IhcA>?		M3L3UmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMV1Z\|IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhGWjJid3n0bEBKSzVyIH;mJFIvOiEQvF2=	MVqyNVA5ODZ{OR?=
COR-L23	NVPTS25IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWSxNEDPxE1?	M1zxd\|czKGh?	Mnf3SG1UVw>?	NVq0NohYT0l3ME2xMlEh\|ryP	NXrmR5JROjFyOEC2OFc>
DU145	NEjDfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFX1bpYyOCEQvF2=	NGPDb2E4OiCq	MV3EUXNQ	M3X0T2dKPTB;MT6wOUDPxE1?	M2mxeVIyODhyNkS3
LoVo	Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH[wbZgyOCEQvF2=	MVe3NkBp	NFrRTGlFVVOR	MnvDS2k2OD1zLkeg{txO	NEPte4czOTB6ME[0Oy=>
MCR5-SV2	NGmx[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nncFExKM7:TR?=	MUC3NkBp	NIjtclRFVVOR	Mlf4S2k2OD1{LkGg{txO	NUfm[ZdvOjFyOEC2OFc>
HCT116	M2\oXWtqdmG\|ZTDBd5NigQ>?	NXTtWJdzOzBizszN	M4XKUlMxKGh?	MnHNSG1UVw>?	NIjqNmlKdmirYnn0bY9vKG:oIFjERWM3KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBidHCqYT30eYJ2dGmwIHHj[ZR6dGG2aX;u	NH6wO2czOTB6ME[0Oy=>
HCT116	MWPLbY5ie2ViQYPzZZk>	MlvLN\|Ah\|ryP	M2nHSlMxKGh?	MWXEUXNQ	NG\ieXdKdmirYnn0bY9vKG:oIFjERWMyKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{UzliYXPleJlt[XSrb36=	M2f5N\|IyODhyNkS3
U937	MVXLbY5ie2ViQYPzZZk>	NX;Lcm4zPSEQvF2=	M3jsTFI1KGh?	NG\HUGFFVVOR	NX3jcIR[UW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{m=	MV2yNVI6OjR7Mh?=
U937	MYrLbY5ie2ViQYPzZZk>	NHzZUmU2KM7:TR?=	NVTOZol5OjRiaB?=	M1fifmROW09?	NUDDPFduUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{G4	NVfYPHc6OjF{OUK0PVI>
U937	M{PBTWtqdmG\|ZTDBd5NigQ>?	Mn;tOUDPxE1?	Mnn0NlQhcA>?	MUjEUXNQ	M4nIVGlvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDv[kBx[W5vYXPleJlt[XSnZDDobZN1d26nIFi0JIxmfmWu	MoHPNlEzQTJ2OUK=
U937	Mo\DT4lv[XOnIFHzd4F6	NYqwcGM2PSEQvF2=	NXX4dHpTOTVibXnu	NVLCW5M3TE2VTx?=	NEj3eJdKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjDs[ZZmdA>?	Ml6yNlEzQTJ2OUK=
A2780	NXOwPXV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlnoPVYhcA>?	NIXnWW9FVVOR	MXzJR\|UxRTFwNkKg{txO	NHHjW4QzOTZ\|NESzNC=>
COLO205	NHvqR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYO5OkBp	NH3zOnZFVVOR	MkP0TWM2OD1{LkGyJO69VQ>?	M36w[lIyPjN2NEOw
Hep3B	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYHUXlBlPDhiaB?=	M1vkemROW09?	MmTPS2k2OD1zLkKxJO69VQ>?	NVHhfZc{OjF5MUKxOFY>
GM11272	MYLGeY5kfGmxbjDBd5NigQ>?	NEnveFgyODBibl2=	NH71fGI4OiCq	NWTWUllLTE2VTx?=	M1zUe3Jm[WO2aY\heIlwdiCxZjDN[WNxOiCvdYThcpQh\XiycnXzd4lwdiCjdDCxNEB1dyBzMECgcm0>	M2izZ\|IyQDRyN{G2
CFBE41o	M1\ZR2tqdmG\|ZTDBd5NigQ>?	NFPTNpY2KM7:TR?=		M3HjbmROW09?	NV\Ddoo{TG:5bjDy[Yd2dGG2aX;uJI9nKEiGQVO3JIF1KDBwMjD0c{A2KHWP	NYexeYpHOjF7OES5OVg>
CFBE41o	Mn;ESpVv[3Srb36gRZN{[Xl?	NWfnVHZGOSEQvF2=	M2LDXlI1KGh?	NWPPO2NrTE2VTx?=	MmfUVoV{fG:{YYTpc44hd2ZiQ1\UVkBl\Wy2YV[1NFghdXW2YX70JJRz[W[oaXPrbY5oKHSxIHPlcIwhe3W{ZnHj[UBieyCpbInjc4Zwem2\|	MnrqNlE6QDR7NUi=
DU145	MonET4lv[XOnIFHzd4F6	MWKyMlUh\|ryP	M2PDeVI1KGh?	NXLo[YdGTE2VTx?=	M{fObWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YheDJzd3HmNUBxem:2ZXnuJIV5eHKnc4Ppc44>	MWSyNlI3ODF4Nh?=
DU145	MlnMT4lv[XOnIFHzd4F6	NEDXTpA2KM7:TR?=	MWKyOEBp	M3OzbmROW09?	Mon0TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUhUDRiYXPleJlt[XSrb36=	M13vTVIzOjZyMU[2
DU145	M1O2WGtqdmG\|ZTDBd5NigQ>?	Mn30OUDPxE1?	MmixNlQhcA>?	MkjaSG1UVw>?	MoG1TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUhUDNiaInw[ZJi[2W2eXzheIlwdg>?	NXrHcnZrOjJ{NkCxOlY>
786-0	NEHl[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDlUog3NjJizszN	MVe3NkBp	MVLEUXNQ	MnnkS2k2OD1\|LkKg{txO	NUPZcWprOjJ2M{W2Olk>
A498	NFvtWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\iRlYvOiEQvF2=	MWe3NkBp	MUHEUXNQ	M3jkcmdKPTB;MT62JO69VQ>?	Ml\oNlI1OzV4Nkm=
A549/ATCC	NYj0e4loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTHOk4zKM7:TR?=	NFy4Too4OiCq	M{LNfGROW09?	MWDHTVUxRTFwNjFOwG0>	NVPFcXJvOjJ2M{W2Olk>
ACHN	NH\5SWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rONVYvOiEQvF2=	MUC3NkBp	M2C5fWROW09?	NUPTTVNST0l3ME2xMlMh\|ryP	NX7HW4FMOjJ2M{W2Olk>
BT549	NWTPeItCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3T0fVYvOiEQvF2=	MUO3NkBp	MoH6SG1UVw>?	MmXGS2k2OD1zLkOg{txO	MVmyNlQ{PTZ4OR?=
EKVX	NGny[\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL4PXg6Pi5{IN88US=>	MmXQO\|IhcA>?	MmrZSG1UVw>?	NXLCVWJJT0l3ME2xMlMh\|ryP	M2fLcFIzPDN3Nk[5
HCT15	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzzR4E3NjJizszN	NWW3cmdyPzJiaB?=	MlnpSG1UVw>?	MXrHTVUxRTJwNTFOwG0>	MmG1NlI1OzV4Nkm=
HOP92	NEm3OIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUG2MlIh\|ryP	MYO3NkBp	MUjEUXNQ	Ml3HS2k2OD12IN88US=>	MkH2NlI1OzV4Nkm=
IGROV1	Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\LUFVbPi5{IN88US=>	M{jz[lczKGh?	MWnEUXNQ	M17DNWdKPTB;MT6zJO69VQ>?	M1LtWFIzPDN3Nk[5
LOXIMVI	NUHTfm8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLuOk4zKM7:TR?=	MljjO\|IhcA>?	MX7EUXNQ	NH;1PFFIUTVyPUGg{txO	NVvteHhCOjJ2M{W2Olk>
M14	NVX0VlVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfJbZQ3NjJizszN	NVnzbJN5PzJiaB?=	NFPBbppFVVOR	M3zVXWdKPTB;MT6zJO69VQ>?	MX6yNlQ{PTZ4OR?=
MALME-3M	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f0VlYvOiEQvF2=	NXO4WoJJPzJiaB?=	NWPzSVNTTE2VTx?=	MnXJS2k2OD1yLkOyJO69VQ>?	MYqyNlQ{PTZ4OR?=
MCF10A	NXn6UYRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;mflYvOiEQvF2=	Ml:xOFghcA>?	M1fJb2ROW09?	MkGzS2k2OD17Lk[g{txO	NIK0dWszOjR\|NU[2PS=>
MDA-MB-435	NIXVRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;DOk4zKM7:TR?=	MlnhO\|IhcA>?	Ml;mSG1UVw>?	NVv0WXo4T0l3ME2wMlUh\|ryP	NGTkWI4zOjR\|NU[2PS=>
MDA-MB-468	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fCXFYvOiEQvF2=	Mn;LO\|IhcA>?	M1;rSGROW09?	NVLDWFdwT0l3ME2wMlY{KM7:TR?=	M4LMTVIzPDN3Nk[5
MOLT4	M3:1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3TUG9oPi5{IN88US=>	MmC5O\|IhcA>?	NHm0eWlFVVOR	NH:yb4xIUTVyPUCuOEDPxE1?	NYHsXFR{OjJ2M{W2Olk>
NCI-ADR-RES	NGHBOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jZOFYvOiEQvF2=	NHTTR4s4OiCq	NGHsZmFFVVOR	M4TsRmdKPTB;MD6xOkDPxE1?	M3LoS\|IzPDN3Nk[5
NCI-H23	MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjSOk4zKM7:TR?=	NI\2SWQ4OiCq	NU\Ge5pMTE2VTx?=	NFXGWFdIUTVyPUGg{txO	MnXGNlI1OzV4Nkm=
NCI-H322M	NGPpTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETlTWw3NjJizszN	NYjmZ4Y6PzJiaB?=	NYHtZYNETE2VTx?=	NX3FNGI4T0l3ME2wMlc6KM7:TR?=	M3;K[lIzPDN3Nk[5
NCI-H460	MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPmcZg3NjJizszN	NIrCToQ4OiCq	M4TjPGROW09?	MX7HTVUxRTBwN{mg{txO	MnXSNlI1OzV4Nkm=
NCI-H522	NFq3b5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFy0blY3NjJizszN	MmHGO\|IhcA>?	MWrEUXNQ	MVPHTVUxRTBwNTFOwG0>	MVmyNlQ{PTZ4OR?=
OVCAR3	M3Ozd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX[2MlIh\|ryP	MXy3NkBp	M4f5XGROW09?	NH;2PW5IUTVyPUGuN{DPxE1?	M3TUOFIzPDN3Nk[5
OVCAR4	M2nCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HUUlYvOiEQvF2=	Ml60O\|IhcA>?	MXnEUXNQ	M4\semdKPTB;NDFOwG0>	NYLhOmVPOjJ2M{W2Olk>
OVCAR5	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV:2MlIh\|ryP	NGjl[Ww4OiCq	MmLDSG1UVw>?	NX:4VI9iT0l3ME2wMlc6KM7:TR?=	MWOyNlQ{PTZ4OR?=
OVCAR8	NUHSZVJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX:2MlIh\|ryP	MXy3NkBp	NGDiSGVFVVOR	MV;HTVUxRTBwNTFOwG0>	NVH0Wmk3OjJ2M{W2Olk>
RXF393	MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LHVlYvOiEQvF2=	MorpO\|IhcA>?	NHyzbZhFVVOR	MXLHTVUxRTFwMzFOwG0>	MVOyNlQ{PTZ4OR?=
SF268	NGDMWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDGW25ZPi5{IN88US=>	NXzvZo95PzJiaB?=	MlXQSG1UVw>?	Mo[zS2k2OD1zLk[g{txO	NVjRfodjOjJ2M{W2Olk>
SF295	NFfMNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDjVFI3NjJizszN	NIPJTmQ4OiCq	NUfB[Vg1TE2VTx?=	MU\HTVUxRTFwNjFOwG0>	NY\uXmhoOjJ2M{W2Olk>
SF539	M{fnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfXOk4zKM7:TR?=	NGezbHo4OiCq	MonOSG1UVw>?	MWjHTVUxRTJizszN	M2rjclIzPDN3Nk[5
SK-MEL-2	M4TCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWD6XWp4Pi5{IN88US=>	M3zHSVczKGh?	MWjEUXNQ	NFy2[ZJIUTVyPUGuN{DPxE1?	NV\zdJU4OjJ2M{W2Olk>
SK-MEL-28	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY[2MlIh\|ryP	NUX1ZlBvPzJiaB?=	NH30e5dFVVOR	MXrHTVUxRTFizszN	NF;oeoszOjR\|NU[2PS=>
SK-MEL-5	NEHp[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W5PVYvOiEQvF2=	Mor3O\|IhcA>?	M{jINGROW09?	NX70TYRvT0l3ME2wMlY{KM7:TR?=	NIL3OZYzOjR\|NU[2PS=>
SKOV3	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHNdWw3NjJizszN	MVi3NkBp	MYnEUXNQ	MmfKS2k2OD1zIN88US=>	MkG0NlI1OzV4Nkm=
SN12C	MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojkOk4zKM7:TR?=	MVK3NkBp	MYHEUXNQ	MnSwS2k2OD1{IN88US=>	MmDaNlI1OzV4Nkm=
SNB19	NWq1NY84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvEUG43NjJizszN	MnrPO\|IhcA>?	NX3WUXdqTE2VTx?=	NH\IPXdIUTVyPUCuOlMh\|ryP	MVOyNlQ{PTZ4OR?=
SNB75	MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUS2MlIh\|ryP	MYC3NkBp	MmO3SG1UVw>?	MnfCS2k2OD1yLke5JO69VQ>?	NXPlUIo1OjJ2M{W2Olk>
SR	Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWO2MlIh\|ryP	Mm\oO\|IhcA>?	M3PkeWROW09?	NVW3UIZGT0l3ME2wMlQh\|ryP	Mme5NlI1OzV4Nkm=
T47D	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\Sb\|YvOiEQvF2=	MYm3NkBp	MnHjSG1UVw>?	M2LG[WdKPTB;MD61JO69VQ>?	MnziNlI1OzV4Nkm=
TK10	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[5TlYvOiEQvF2=	NV;aOnltPzJiaB?=	NGjVZYlFVVOR	M2TiOWdKPTB;MD62N{DPxE1?	NWO0dHI5OjJ2M{W2Olk>
UACC257	MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXP2R5ZoPi5{IN88US=>	MlrQO\|IhcA>?	MUPEUXNQ	MkjTS2k2OD1yLkWg{txO	NGHNTZkzOjR\|NU[2PS=>
UACC62	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVu2MlIh\|ryP	MlO0O\|IhcA>?	M3vWSmROW09?	M2DBTWdKPTB;MD60JO69VQ>?	NVe1bVZQOjJ2M{W2Olk>
UO31	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTyOk4zKM7:TR?=	MljLO\|IhcA>?	M4T1c2ROW09?	MVPHTVUxRTBwNTFOwG0>	MnTVNlI1OzV4Nkm=
Hep3B	NUPQXXc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUm0PEBp	NIrPdW9FVVOR	M1q5SmdKPTB;MD62PUDPxE1?	MVuyNlQ{QTh4Mx?=
BE(2)-C	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHLaTXg4OiCq	NGPzelVFVVOR	NGO3b2xKSzdyPUKg{txO	MmniNlI6OzJ\|MU[=
Bel7402	MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGTnPJE4OiCq	NGjmRZRFVVOR	MUXHTVkxRTF5IN88US=>	NES4fWczOzB4MUO3Oi=>
Bel7404	M2LYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEm2XYo4OiCq	NIn2S5hFVVOR	NVnhU3lzT0l7ME2xPEDPxE1?	MXqyN\|A3OTN5Nh?=
BGC823	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnvwO\|IhcA>?	M{Cyd2ROW09?	M4DEbWdKQTB;Nz61JO69VQ>?	NGfp[4kzOzB4MUO3Oi=>
MGC803	NWHBVIRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NG\OZpA4OiCq	NYXL[2x1TE2VTx?=	MnH1S2k6OD1zMD64JO69VQ>?	M3;IelI{ODZzM{e2
SGC7901	NYrzNI8{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV23NkBp	NETV[YZFVVOR	M330UmdKQTB;OT60JO69VQ>?	MkL4NlMxPjF\|N{[=
SKHEP1	Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXi3NkBp	MmHmSG1UVw>?	MmCwS2k6OD1zNzFOwG0>	NFKyV4YzOzB4MUO3Oi=>
SMMC7721	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1PudFczKGh?	Mlq1SG1UVw>?	MV3HTVkxRTJyIN88US=>	NV\nNlBJOjNyNkGzO\|Y>
NUGC3	NHTXWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvMNVAh\|ryP			NFzZZoZIUT1{Lkm0JO69VQ>?	NX;nPFRGOjNzNkOzN\|I>
A2780 CisR	MoruT4lv[XOnIFHzd4F6		MkXnNVghcA>?		NIHY[I9KdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOFQh\|ryP	MojQNlMzPTJ4MEO=
CAL27 sens	Mk[1T4lv[XOnIFHzd4F6		NV2zTlJvOThiaB?=		NV7tWlZ5UW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM3KM7:TR?=	NHnkb2kzOzJ3Mk[wNy=>
CAL27 CisR	Mn7UT4lv[XOnIFHzd4F6		NHPwS20yQCCq		MX3Jcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	MVOyN\|I2OjZyMx?=
KYSE-510 CisR	M2i1RWtqdmG\|ZTDBd5NigQ>?		MnTLNVghcA>?		NY[3OZgzUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlU6KM7:TR?=	M2rZWVI{OjV{NkCz
KYSE-510 sens	MVfLbY5ie2ViQYPzZZk>		M2rsV\|E5KGh?		MkPUTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkeg{txO	NU\5SJBROjN{NUK2NFM>
MDA-MB-231 sens	NGSwfmpMcW6jc3WgRZN{[Xl?		NEXzfHgyQCCq		M4TGSWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	NVXVWo5IOjN{NUK2NFM>
MDA-MB-231 CisR	NIrqOphMcW6jc3WgRZN{[Xl?		M4OwNlE5KGh?		NEfJZ3FKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOlEh\|ryP	NEm1bmIzOzJ3Mk[wNy=>
ES2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXruSFdRPDhiaB?=	NIjTVHhFVVOR	M2rnd2lEPTB;MUKuO{DPxE1?	MXOyN\|Q6OzR2OR?=
MDA-MB-231	MVjLbY5ie2ViQYPzZZk>	NE\wOW4yOCEQvF2=	MUWzNEBucW5?	MoLWSG1UVw>?	MlXLTY5pcWKrdHnvckBw\iCKRFHDNoE>	M1LoUVI{PDl\|NES5
MDA-MB-231	NY\ObHRqU2mwYYPlJGF{e2G7	NHH1XIUyKM7:TR?=	MkDCNlQhcA>?	NGjxOHBFVVOR	NH6ySZBKdmirYnn0bY9vKG:oIFjERWM3KGG\|c3Xzd4VlKGG\|IHHj[ZR6dGG2aX;uJIxmfmWuczDv[kB1fWK3bHnu	M{Pid\|I{PDl\|NES5
HS68	NFX3NWtEgXSxdH;4bYMhSXO\|YYm=	NW\XfGVKOTBizszN	M{HmfVczKGh?	M1jmZWROW09?	NFrWVHFKSzVyPUSuOkDPxE1?	MlHENlM2PzB3NEK=
MEF	NXqySWtzS3m2b4TvfIlkKEG\|c3H5	NU\LO206OTBizszN	NUDWZ4gyPzJiaB?=	M3HKXWROW09?	M13zSWlEPTB;ND60JO69VQ>?	M{PJS\|I{PTdyNUSy
BGC823	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX7EUXNQ	MVLHTVUxRTNwMEmg{txO	Mn71NlM3ODF5ME[=
High5	MmrPT4lv[XOnIFHzd4F6		NYfWXoFCOjRiaB?=		MYnJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVO2JJdqfGhiSVO1NEBw\iByLkC5JO69VQ>?	MV6yN\|YxOjV{Mx?=
High5	MkjST4lv[XOnIFHzd4F6		NFXJbIwzPCCq		MUHJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxJJdqfGhiSVO1NEBw\iByLkGyJO69VQ>?	NFPoPZEzOzZyMkWyNy=>
High5	NV3HTFdpU2mwYYPlJGF{e2G7		NIj6e\|EzPCCq		M33ScGlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Mhf2m2aDDJR\|UxKG:oIECuNVch\|ryP	MX2yN\|YxOjV{Mx?=
A549	NFzBdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWnifnBKTE2VTx?=	MUHJR\|UxRTFwMEe5JO69VQ>?	NHy1dmgzOzZ2NEKxNC=>
HCT116	M{P0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYTUVYc5TE2VTx?=	NYK4S5FyUUN3ME2wMlc2PyEQvF2=	Ml7pNlM3PDR{MUC=
K562	NIe3[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFvQUWVFVVOR	Moj0TWM2OD1yLk[0OUDPxE1?	M4LRZVI{PjR2MkGw
GBC-SD	MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITOOG82KM7:TR?=	MkTCO\|IhcA>?	MmmxSG1UVw>?	MX7JR\|UxRTF2Lkig{txO	MV[yN\|cxPzJ4MB?=
HGC27	M17VVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGT4UHE2KM7:TR?=	MV[3NkBp	NVjlTox6TE2VTx?=	NEOzeHJKSzVyPUWuOEDPxE1?	NY\Xe2xiOjN5MEeyOlA>
HL60	MXnLbY5ie2ViQYPzZZk>	MVG1JO69VQ>?	MojXNlQhcA>?	MlvvSG1UVw>?	MY\Jcohq[mm2aX;uJI9nKEiGQVO=	MY[yN\|cxPzJ4MB?=
Vero	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3m5TlczKGh?	MYTEUXNQ	NYTOXox4UUN3ME2wMlkh\|ryP	NUPm[YRuOjN5OE[0OVI>
NCI60	NXn0[41bS3m2b4TvfIlkKEG\|c3H5		NEj6c4g1QCCq	NV3nfldqTE2VTx?=	MkP5S2k:OC53MzFOwG0>	MViyOFAyPTN{Nx?=
SW620	MlLJR5l1d3SxeHnjJGF{e2G7		NGn4NpM1QCCq	NGiweo1FVVOR	NYr1UJgxT0l;MD61OEDPxE1?	MnXsNlQxOTV\|Mke=
U251	NWLMbJNtS3m2b4TvfIlkKEG\|c3H5		NUjFXldRPDhiaB?=	M36xTWROW09?	NGnlR4lIUT1zLkWzJO69VQ>?	NUTIZWxNOjRyMUWzNlc>
KM12	NUK3cWNuS3m2b4TvfIlkKEG\|c3H5		NUDKcIdDPDhiaB?=	NH3ieYdFVVOR	M2XCZmdKRTFwOEig{txO	M1PQNFI1ODF3M{K3
Hs578T	M4HSbGN6fG:2b4jpZ{BCe3OjeR?=		NFzaUnQ1QCCq	MUjEUXNQ	Mn\zS2k:PC56MzFOwG0>	M4TxflI1ODF3M{K3
MDA-MB-231	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYO0PEBp		MYDJR\|UxRTBwMU[g{txO	MUCyOFA6PTBzNh?=
MCF7	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYnMboVLPDhiaB?=		Mln1S2k:OC52NTFOwG0>	MVGyOFEyQTV3NR?=
MDA-MB-435	NGDmVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV[0PEBp		NIrORnNIUT1yLki4JO69VQ>?	NYWwVWlFOjRzMUm1OVU>
AsPC1	NHH0fYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLHOVdGOzBizszN	NHe4PXM1QCCq	MofuSG1UVw>?	M1vkeWlEPTB;Mz62OkDPxE1?	MmjXNlQyQDV\|N{i=
Jurkat E6.1	MlroT4lv[XOnIFHzd4F6		MVWyJIg>	NGfnV\|VFVVOR	M{nOdGlvcGmkaYTpc44hd2ZiSFTBR\|Qhf2m2aDDJR\|UxKG:oIECuNFQh\|ryP	NFvNUoQzPDJ4MUi2Ni=>
KG1	M2f4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF[5Tno1QCCq		MnfDTWM2OD1zLkG1JO69VQ>?	NX\hR20xOjR3MkWwNFM>
HEL	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUO0PEBp	M2DOXGROW09?	NWftT2Y3UUN3ME2wMlQ6KM7:TR?=	NIHLUnEzPDZ7NEC1OS=>
HSC3	MkPZR5l1d3SxeHnjJGF{e2G7		MUixNkBp	NFGzNoJFVVOR	MkfmTWM2OD1yLkexJO69VQ>?	NVXLW25{OjR5Nk[1OlA>
HT-29	NUTOXopiS3m2b4TvfIlkKEG\|c3H5		M2HGbVEzKGh?	MV3EUXNQ	NXm3U\|QzUUN3ME2wMlczKM7:TR?=	MljsNlQ4PjZ3NkC=
KB	M2fBcmN6fG:2b4jpZ{BCe3OjeR?=		NGCyZngyOiCq	NETNT\|lFVVOR	M2TJN2lEPTB;MD63OUDPxE1?	MmLsNlQ4PjZ3NkC=
H460	M1X6N2N6fG:2b4jpZ{BCe3OjeR?=		MW[xNkBp	NFu2PJJFVVOR	M3fvVmlEPTB;MD64NkDPxE1?	Ml;3NlQ4PjZ3NkC=
MONE1	M3TuTWN6fG:2b4jpZ{BCe3OjeR?=		M13KTVEzKGh?	M4rve2ROW09?	NYnNNHdwUUN3ME2xMlE5KM7:TR?=	Mm\0NlQ4PjZ3NkC=
MKN45	NGPPd2REgXSxdH;4bYMhSXO\|YYm=		M1;SUlEzKGh?	MXfEUXNQ	NULGZ5J[UUN3ME2xMlI2KM7:TR?=	NXHuRWQ3OjR5Nk[1OlA>
TSGH	MnTER5l1d3SxeHnjJGF{e2G7		NV7FTJZFOTJiaB?=	NXW3cVJVTE2VTx?=	NEXzSIJKSzVyPUKuNFkh\|ryP	MkLpNlQ4PjZ3NkC=
HL60	Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVPmSnVsPzJiaB?=	MW\EUXNQ	MXnHTVUxRTBwOUOg{txO	M4m4OlI1QTByNUCw
HEK293	NGXTU\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEPFNJU4OiCq	NIXoeYVFVVOR	NEPzN\|NIUTVyPUGzJO69VQ>?	M{DXcVI1QTByNUCw
Jurkat	NVe4SnhCS3m2b4TvfIlkKEG\|c3H5	MX[xNFAh\|ryP	NWXlXIw2PzJiaB?=		NG\hc2RIUTVyPUCuPUDPxE1?	NWrpOYt7OjR7MEC3OFM>
GM15850	MofNT4lv[XOnIFHzd4F6	Mo\kNk42KM7:TR?=	MlrUPVYhcA>?	MnHRSG1UVw>?	M2DwSYRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGy7c3nu[UAyPCCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	NGizRocyPjl{MUO2Oy=>
GM15850	M1jnTGtqdmG\|ZTDBd5NigQ>?	MX6yMlUh\|ryP	NUPOR21rQTZiaB?=	M2jibmROW09?	NV;RZ3Q2\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDViYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NVjjbFFCOTZ7MkGzOlc>
GM15850	M1zXbWtqdmG\|ZTDBd5NigQ>?	MYeyMlUh\|ryP	NHv4T4k6PiCq	MVPEUXNQ	MYfkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVIh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M123eFE3QTJzM{[3
GM15850	NU[2N\|FRU2mwYYPlJGF{e2G7	NVLzVlhIOi53IN88US=>	MkjlPVYhcA>?	NFi2fndFVVOR	NF\TSYZld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCueYPpcoUhQSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	NHy5Z3MyPjl{MUO2Oy=>
GM15850	MWHLbY5ie2ViQYPzZZk>	MnHHNk42KM7:TR?=	NG\UbWY6PiCq	M4rBe2ROW09?	MVrkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgPEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	M2nWblE3QTJzM{[3
GM15850	NEDUSldMcW6jc3WgRZN{[Xl?	MV:yMlUh\|ryP	MVe5OkBp	MVzEUXNQ	MVzkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVYh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NWHVe\|dyOTZ7MkGzOlc>
GM15850	M4\HUGZ2dmO2aX;uJGF{e2G7	M13TNFUh\|ryP	MnfqNVIhcA>?	M{DjbWROW09?	NF;hRXNp[XNibn:g[YZn\WO2IH;uJGZZViCvUl7BJIV5eHKnc4Ppc44>	NFmz[ogyPjl{MUO2Oy=>
U937	MVTLbY5ie2ViQYPzZZk>	MoHNOUDPxE1?	NFnLUmwzPCCq	MmfhSG1UVw>?	NGrrbVNp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=	NWfndHJNOTd2NEe3OVA>
U937	Ml7ZT4lv[XOnIFHzd4F6	NX7wcnJjOSEQvF2=	M1\tS\|I1KGh?	M{LJfGROW09?	M330ZohieyCwbzDl[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	NHLrZZgyPzR2N{e1NC=>
PANC1	NX\VcXF4TnWwY4Tpc44hSXO\|YYm=	M1nkTVEh\|ryP	M{\tOFI1KGh?		MkjN[I9meyCwb4SgbY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36=	NXjqOVdpOTd3OEi3OFQ>
PANC1	NUH3SHR4TnWwY4Tpc44hSXO\|YYm=	MkfpNUDPxE1?	NWPPbXdoPDhiIHi=		MWTkc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	MlLZNVc2QDh5NES=
Caco-2	NUHLRlNuTnWwY4Tpc44hSXO\|YYm=	Ml;iOUDPxE1?	MmrjNlQhcA>?	NVjScnk3TE2VTx?=	NID5eo5ld2W\|IH7veEBqdmS3Y3WgVFIyX0GIMTDn[Y5mKGW6cILld5Nqd25?	NGTnNoczODF2M{i0NC=>
SCC4	MoXzSpVv[3Srb36gRZN{[Xl?	NITHd4wyKM7:TR?=	Mki3NVAhdWmw	MVTEUXNQ	M1q2XohieyCwbzDh[49vcXO2IHHjeIl3cXS7IHH0JHZFWiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhS1mSMkSg[4Vv\SCneIDy[ZN{cW:w	MWeyNFQ2OjJ{NR?=
A549	MUfGeY5kfGmxbjDBd5NigQ>?	M4HZTVUh\|ryP	NXfXbJpWOyCq	MlP2SG1UVw>?	NIf1XnBld2W\|IH7veEBqdmS3Y3WgZZV1d3CqYXf5JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFzDN2lK	MkH5NlA5PTV{MEi=
HCT116	MkPBT4lv[XOnIFHzd4F6	M1TXeVAvOyEQvF2=	NVjXbYs{OzBiaB?=	NEjmeYRFVVOR	M1G2eYRw\XNibn;0JIlvcGmkaYSgTGRCSzFiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGirc4TvcoUhUDONOTDhZ4V1gWyjdHnvci=>	MmXPNlExQDB4NEe=
HepG2	M1T3ZmZ2dmO2aX;uJGF{e2G7	M{jXVlExKM7:TR?=	NH:2RXUzPCCq	NV;vfVZOTE2VTx?=	NXnKZ45L\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCqeYDldoFk\XS7bHH0bY9vKG:oIIC1Ny=>	NV7uNpdtOjF3NEi1PFI>
GM11272	NXXP[VdqTnWwY4Tpc44hSXO\|YYm=	MY[wMlEh\|ryP	MlX6O\|IhcA>?	M2D0SWROW09?	MWjkc4V{KG6xdDDy[YFkfGm4YYTlJG1mS3B{IH31eIFvfCCneIDy[ZN{cW:w	M3[xNVIyQDRyN{G2
MDA-MB-231	NIXPSo1McW6jc3WgRZN{[Xl?	M3fGNFExKM7:TR?=	NYHleo4zPSCvaX6=	MYrEUXNQ	MVXkc4V{KG6xdDDpcohq[mm2IFjERWMz[Q>?	MXSyN\|Q6OzR2OR?=
MDA-MB-231	MnnTT4lv[XOnIFHzd4F6	M3zETlEh\|ryP	NWi2PI5{OjRiaB?=	NHm4eFNFVVOR	NHT0UVlld2W\|IH7veEBqdmirYnn0JGhFSUN4IHHzd4V{e2WmIHHzJIFk\XS7bHH0bY9vKGyndnXsd{Bw\iC2dXL1cIlv	NEPKdGQzOzR7M{S0PS=>
K562	M2qzXWtqdmG\|ZTDBd5NigQ>?				NHnEcItld2W\|IH7veEBqdmirYnn0JGhFSUN?	MUCyN\|U6OTFzMR?=
Jurkat	M1vSZ2N6fG:2b4jpZ{BCe3OjeR?=	M3r2VlIxKM7:TR?=	NHXRe5k4OiCq	M1LWOmROW09?	NXjWUGxkdm9iY4n0c5RwgGmlaYT5JIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9v	NFL5cXkzPDNyNEO0PC=>
HCT116	M3rYeGFxd3C2b4Ppd{BCe3OjeR?=	MnzIN{DPxE1?	NEDCZVMzPCCq	MmW1SG1UVw>?	MWnkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKHB3MzDwdo91\WmwIHzleoVt	MljONlQ4PjZ3NkC=
KASUMI-1	M2TITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHCSpRKSzVyPUm5MlE4KG6P	NHPa[4hUSU6JRWK=
KARPAS-45	M{LNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXiTWM2OD1zN{OuPFkhdk1?	MoXwV2FPT0WU
BHT-101	NUO2OVBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVeyV3J2UUN3ME2yOFQvOThibl2=	NXzxO5dvW0GQR1XS
H9	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\WNGxKSzVyPUK1OU4xPCCwTR?=	MlLRV2FPT0WU
PA-1	M2jSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;STWM2OD1{OE[uNlYhdk1?	M3;LTXNCVkeHUh?=
NEC8	Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rqWmlEPTB;Mki5MlM5KG6P	Mn;XV2FPT0WU
MHH-PREB-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTJ7ND61N{BvVQ>?	M3\IN3NCVkeHUh?=
NB7	NVrEUpN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jiWGlEPTB;M{S1Mlc1KG6P	NESwSIdUSU6JRWK=
A3-KAW	MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTRyMD61PUBvVQ>?	NWjxUVRIW0GQR1XS
NB69	NYjid4k{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnjdWtFUUN3ME20NVEvPzFibl2=	M1XBbnNCVkeHUh?=
EoL-1-cell	NYTp[ZlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrYfHpKSzVyPUS1OFI2KG6P	NXntWJdtW0GQR1XS
CHP-212	MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1W0T2lEPTB;NEW3MlU{KG6P	M1TCXHNCVkeHUh?=
C2BBe1	MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHP3SJRKSzVyPUS3Nk4yQSCwTR?=	MYfTRW5ITVJ?
697	Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTR5Mz60NUBvVQ>?	MXLTRW5ITVJ?
BCPAP	NFf0eWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTucHhmUUN3ME21NFEvPDJibl2=	MmHQV2FPT0WU
L-363	NXrJbHR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHX2bFNKSzVyPUWwN{4yKG6P	Ml\lV2FPT0WU
ES8	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYL6dYVCUUN3ME21NlMvPTNibl2=	NWXpZo5IW0GQR1XS
BE-13	NWGxPYpST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlW0TWM2OD13Mk[uPVYhdk1?	M1r1W3NCVkeHUh?=
CTB-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWP3VVM2UUN3ME21N\|cvQTJibl2=	MX\TRW5ITVJ?
HD-MY-Z	MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIC0TlFKSzVyPUWzPE4yOyCwTR?=	NVTnWYUxW0GQR1XS
NKM-1	NUP4V\|NvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTV2ND6yO{BvVQ>?	NUi3SJY1W0GQR1XS
NCI-H720	M1PzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\XSGlEPTB;NU[wMlE5KG6P	MnL4V2FPT0WU
KY821	NVK4W\|MzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTV4Mz6yOUBvVQ>?	NYewPXBRW0GQR1XS
OVCAR-5	M{Tmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXn2RZBGUUN3ME21O\|YvOTFibl2=	NEO4bFhUSU6JRWK=
CTV-1	NFHxZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrifoFKSzVyPUW4NU42PiCwTR?=	Ml7vV2FPT0WU
P12-ICHIKAWA	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrDbo1KSzVyPUW5Ok42OSCwTR?=	NU[3XItOW0GQR1XS
DB	MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTV7OD61O{BvVQ>?	M4TkT3NCVkeHUh?=
CHL-1	NUfRXYE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3Yb4xLUUN3ME22OFIvODhibl2=	NV;3eXpNW0GQR1XS
A4-Fuk	NYrwcY5bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTZ2ND65NUBvVQ>?	NXG3XXJvW0GQR1XS
MV-4-11	NEPpTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHW1TWNKSzVyPU[1PU4yKG6P	MYfTRW5ITVJ?
RPMI-8226	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTZ5OD6xPEBvVQ>?	M4Sw[HNCVkeHUh?=
NB14	MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3Xx[WlEPTB;Nkm2Mlk2KG6P	NU\pUXU6W0GQR1XS
DOHH-2	NHHlSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3LVmZKSzVyPUewOk43QCCwTR?=	NEHQeZhUSU6JRWK=
D-423MG	MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DsU2lEPTB;N{C2Mlg6KG6P	NV6yW2dVW0GQR1XS
D-283MED	M{fy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTdzND6xOEBvVQ>?	MlqyV2FPT0WU
ES1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjmTWM2OD15MkSuOEBvVQ>?	MmTwV2FPT0WU
GOTO	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTd{OT6xNkBvVQ>?	MXLTRW5ITVJ?
NCI-H209	MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHKUHFOUUN3ME23NlkvQSCwTR?=	MY\TRW5ITVJ?
MOLT-13	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmm1TWM2OD15M{iuPVghdk1?	M4HpbXNCVkeHUh?=
ATN-1	MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXQR5FIUUN3ME23OFAvOjhibl2=	NWXPdIV2W0GQR1XS
DU-4475	MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvMOJFKSzVyPUe1NU46OSCwTR?=	NWjnVpFiW0GQR1XS
NB10	MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnsTWM2OD15NUGuPVIhdk1?	MUXTRW5ITVJ?
KG-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoKwTWM2OD15N{WuOFUhdk1?	MmnnV2FPT0WU
MOLT-4	NHS0UFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnLcohKSzVyPUe4O{41PiCwTR?=	MVLTRW5ITVJ?
TE-1	M{LCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\ZS2lEPTB;N{mxMlEhdk1?	NELYUnJUSU6JRWK=
SBC-1	NHThbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTd7Mz64OEBvVQ>?	MV;TRW5ITVJ?
HEL	Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXkb\|lKSzVyPUiwOk4xQCCwTR?=	NF;UcFVUSU6JRWK=
SK-MEL-2	M1nKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRThyOT60OEBvVQ>?	NVrHdHllW0GQR1XS
KU812	M4H6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRThzMz6xJI5O	NH3jWodUSU6JRWK=
RPMI-8866	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3r5eWlEPTB;OEGzMlY4KG6P	NIHwNYpUSU6JRWK=
ALL-PO	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRThzND62OkBvVQ>?	M4PXVXNCVkeHUh?=
LU-139	MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;TemlEPTB;OEKyMlg3KG6P	NEnlRmFUSU6JRWK=
RS4-11	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vHVGlEPTB;OEOyMlQ2KG6P	MmOzV2FPT0WU
EW-18	M2rrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTh\|Mj65OkBvVQ>?	NVPDUIFNW0GQR1XS
P30-OHK	Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXwSHhKSzVyPUizOU44KG6P	M4rKUXNCVkeHUh?=
D-566MG	M1TqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTh\|OD62NkBvVQ>?	MYPTRW5ITVJ?
HSC-4	M33S[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojDTWM2OD16NE[uOVEhdk1?	NVzUNmxmW0GQR1XS
QIMR-WIL	NXnEXJNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTh4Mj6wN{BvVQ>?	Mm\iV2FPT0WU
SW954	M3jkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTh4Mz6xOkBvVQ>?	MoPzV2FPT0WU
HGC-27	NGC1[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoroTWM2OD16N{KuN\|Qhdk1?	NUHQbmR1W0GQR1XS
HH	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2i4cWlEPTB;OEm0MlEzKG6P	MVPTRW5ITVJ?
KE-37	NXP3[25xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTHUIVKSzVyPUi5OE43OiCwTR?=	MmTEV2FPT0WU
SK-N-DZ	MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TlWGlEPTB;OUCwMlQ{KG6P	NHTGTnFUSU6JRWK=
J-RT3-T3-5	NWnoeXJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlG0TWM2OD17MUCuOFkhdk1?	MUDTRW5ITVJ?
A427	M2LNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rZeWlEPTB;OUKwMlg1KG6P	NUXDcZdkW0GQR1XS
ECC10	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvNTWM2OD17NEWuPFchdk1?	NGHEN4FUSU6JRWK=
EW-1	NFvHfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PLSmlEPTB;OUS3MlI3KG6P	MXHTRW5ITVJ?
MIA-PaCa-2	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnDTWM2OD17NEmuNVIhdk1?	M2n0TXNCVkeHUh?=
HCC2218	M1frfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTl3OD60PEBvVQ>?	NIW0XZJUSU6JRWK=
HAL-01	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHtTWM2OD17NkiuNFQhdk1?	NUPBN5hzW0GQR1XS
RD	Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYf6WJYxUUN3ME25O\|QvPDVibl2=	M3;wRXNCVkeHUh?=
SK-N-AS	NVLMbIJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1:4fmlEPTB;OUi4MlEhdk1?	MX3TRW5ITVJ?
ML-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1n2SmlEPTB;MT6wNFQxPyEQvF2=	M3jKbHNCVkeHUh?=
MEL-HO	NUWxSY9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnDTWM2OD1zLkCwOVgzKM7:TR?=	MkHUV2FPT0WU
MS-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIP3e45KSzVyPUGuNFA3OTdizszN	MW\TRW5ITVJ?
NCI-SNU-1	NXzjWnJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWq5OHBbUUN3ME2xMlAzOzNzIN88US=>	MYTTRW5ITVJ?
8505C	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\DZmlEPTB;MT6wNlM{OSEQvF2=	NHvib\|dUSU6JRWK=
MN-60	NYTvd5NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTnTWM2OD1zLkCyOlgh\|ryP	M1\SPXNCVkeHUh?=
SAS	NVrJTFgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTFwMESwPFEh\|ryP	MWLTRW5ITVJ?
EFM-19	NHviTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PoWGlEPTB;MT6wOFg4QSEQvF2=	NV;OPGg1W0GQR1XS
Ca9-22	Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfkNI5KSzVyPUGuNFUyODdizszN	M3PwNnNCVkeHUh?=
NBsusSR	NHjM[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTFwMEWxOlYh\|ryP	MUDTRW5ITVJ?
NB13	M{jsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFi0UZFKSzVyPUGuNFU2ODFizszN	NUXXTIJmW0GQR1XS
SF295	NUfZbGlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvzTWM2OD1zLkC2OlI1KM7:TR?=	MWTTRW5ITVJ?
U-2-OS	M2PufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHaTWM2OD1zLkC3PVEyKM7:TR?=	MkHkV2FPT0WU
NCI-H526	NHG3cIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XLVmlEPTB;MT6wPFI6OSEQvF2=	Ml;BV2FPT0WU
KMOE-2	M4DKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnWW3BSUUN3ME2xMlA6PDJ{IN88US=>	MYLTRW5ITVJ?
RCM-1	MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjsTWM2OD1zLkGyNVAzKM7:TR?=	MXvTRW5ITVJ?
MC116	MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TpcWlEPTB;MT6xN\|YzOSEQvF2=	MUHTRW5ITVJ?
NCI-H1092	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVj2OlExUUN3ME2xMlE2PDB4IN88US=>	NGnBRmVUSU6JRWK=
EW-3	NWPMS5ptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHmRm81UUN3ME2xMlE4OjF{IN88US=>	NGC2TYNUSU6JRWK=
HCT-116	NVqwc\|BLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnFc21KSzVyPUGuNVc4PSEQvF2=	NEHsOZJUSU6JRWK=
MC-IXC	NX3BU29lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTFwMUe4PFEh\|ryP	NV;McJlyW0GQR1XS
LB1047-RCC	NXHPO4RzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTFwMUizNVIh\|ryP	NX;RPWw3W0GQR1XS
VM-CUB-1	M3fQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTFwMUmxNFgh\|ryP	MmfGV2FPT0WU
NB5	NXvWfWtET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTFwMUm4OVYh\|ryP	NH3nXlhUSU6JRWK=
SKG-IIIa	MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rtTWlEPTB;MT6yN\|Q3PCEQvF2=	MUDTRW5ITVJ?
HO-1-N-1	NHH1d\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTFwMkO4N\|Uh\|ryP	MkH0V2FPT0WU
EFO-27	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFOzcmdKSzVyPUGuNlUxPDNizszN	NH7zRYlUSU6JRWK=
MHH-NB-11	NY\kT5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPSb4FKSzVyPUGuNlg{OjlizszN	NEPZeohUSU6JRWK=
SW620	NGnacHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjDXXZxUUN3ME2xMlI6ODF6IN88US=>	NVjSb2J{W0GQR1XS
MOLT-16	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLFXolZUUN3ME2xMlI6Pzl5IN88US=>	NETGUWFUSU6JRWK=
NTERA-S-cl-D1	NWfhXFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfoeYhKSzVyPUGuN\|E4PjFizszN	NEe2RWdUSU6JRWK=
VA-ES-BJ	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzLTWM2OD1zLkOyOFc4KM7:TR?=	MmXSV2FPT0WU
HCC1419	M1H5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\FXGlEPTB;MT6zOFAzPyEQvF2=	NGezbXlUSU6JRWK=
NCI-H69	MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;ZVWVKSzVyPUGuN\|QyOTJizszN	NUixVZpNW0GQR1XS
DEL	NF7PV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TlOmlEPTB;MT6zOVE3OiEQvF2=	MnTWV2FPT0WU
LXF-289	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;ifGlEPTB;MT6zOVI1KM7:TR?=	MY\TRW5ITVJ?
EW-11	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\vdo5KSzVyPUGuN\|YxOjZizszN	M1jQSXNCVkeHUh?=
KP-4	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTFwM{ewPFUh\|ryP	NVjPSlhCW0GQR1XS
NOS-1	MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTmXnh4UUN3ME2xMlQyOTl2IN88US=>	MVzTRW5ITVJ?
SK-NEP-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFwNEG2PVMh\|ryP	MlXoV2FPT0WU
LAMA-84	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWL3RlBlUUN3ME2xMlQ{QTR3IN88US=>	M2XMUHNCVkeHUh?=
ES5	NGOxcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3P3SWlEPTB;MT60OFMh\|ryP	M4HRS3NCVkeHUh?=
HuO9	Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjvdXlKSzVyPUGuOFU{PjJizszN	MnuwV2FPT0WU
COLO-684	Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDETWM2OD1zLkS2NVE5KM7:TR?=	MmrDV2FPT0WU
EW-24	MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvpeYtKSzVyPUGuOFY2OzFizszN	NEjqZVNUSU6JRWK=
BV-173	NGrMeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTFwNEeyPVEh\|ryP	MnHCV2FPT0WU
NCI-H1770	M2\je2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTFwNEi1N\|Yh\|ryP	NVPVdGNxW0GQR1XS
HuP-T4	NYriNXB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2[wVWlEPTB;MT60PVMh\|ryP	MUPTRW5ITVJ?
TYK-nu	M{\tPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEP4fHRKSzVyPUGuOFk5PTFizszN	MlH6V2FPT0WU
YH-13	NVnnNVRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jwfmlEPTB;MT60PVg6PCEQvF2=	MYHTRW5ITVJ?
H4	M2rPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XnU2lEPTB;MT61NFkyOiEQvF2=	M3LEc3NCVkeHUh?=
OVCAR-8	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfDTWM2OD1zLkW0OFc4KM7:TR?=	MXXTRW5ITVJ?
NCI-H23	NH;OOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo[2TWM2OD1zLkW0OlQ2KM7:TR?=	NUeyZXRVW0GQR1XS
ES7	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{X2W2lEPTB;MT61OFc4OyEQvF2=	M3\LVnNCVkeHUh?=
COR-L88	M2S4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3W2cGlEPTB;MT61OlQzPCEQvF2=	MXvTRW5ITVJ?
TI-73	M4HERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofVTWM2OD1zLkW5NFYh\|ryP	NVXUflBQW0GQR1XS
RT-112	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTFwNUmyPFQh\|ryP	M33DcHNCVkeHUh?=
HuO-3N1	NI\BZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jDe2lEPTB;MT61PVM5PSEQvF2=	MlfCV2FPT0WU
HC-1	NHL5OGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTFwNUm4OlYh\|ryP	MV7TRW5ITVJ?
HT55	NGrTRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPJNplKSzVyPUGuOlUyOzFizszN	MlHEV2FPT0WU
IA-LM	M4jzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTBR5ZyUUN3ME2xMlY6Ojd6IN88US=>	NELzUpNUSU6JRWK=
EM-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHOxVWhKSzVyPUGuO\|AxOTRizszN	MUTTRW5ITVJ?
MHH-ES-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEP0V4VKSzVyPUGuO\|A1OzVizszN	MVjTRW5ITVJ?
CAL-27	M2PSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nSXmlEPTB;MT63NFYzOSEQvF2=	NF;oOZZUSU6JRWK=
COLO-800	MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTFwN{GxO\|kh\|ryP	NET0dZFUSU6JRWK=
HCE-T	NVziN4JYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2K2OWlEPTB;MT63NVUh\|ryP	NYXyXlhRW0GQR1XS
CAMA-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTFwN{G5O\|Eh\|ryP	Mn\GV2FPT0WU
LOXIMVI	M3nreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjnO3dKSzVyPUGuO\|IyOSEQvF2=	MWjTRW5ITVJ?
NH-12	MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;GTWM2OD1zLkeyOlkyKM7:TR?=	NEfuemNUSU6JRWK=
TCCSUP	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXTTWM2OD1zLkeyPFI6KM7:TR?=	MnL4V2FPT0WU
MDA-MB-361	NUXmN\|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfNRW93UUN3ME2xMlc{OTV5IN88US=>	NV7icFZnW0GQR1XS
EW-16	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33yRWlEPTB;MT63OFExPyEQvF2=	MYXTRW5ITVJ?
SNU-423	NHz3VnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvVV5RGUUN3ME2xMlc2QDJ5IN88US=>	MWjTRW5ITVJ?
Daoy	NYnMSZRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTwdZh3UUN3ME2xMlc3OzF7IN88US=>	NGGwS\|dUSU6JRWK=
ES4	NUHNZmVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrXc2k4UUN3ME2xMlc5PzRzIN88US=>	MYfTRW5ITVJ?
PFSK-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTFwOECzO{DPxE1?	NYTOenlmW0GQR1XS
ES3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTVbXZ4UUN3ME2xMlgzPjhzIN88US=>	NESyPFdUSU6JRWK=
ONS-76	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTFwOEK4PVch\|ryP	M{PjOnNCVkeHUh?=
JVM-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTFwOEW0OVEh\|ryP	NID6fWZUSU6JRWK=
OS-RC-2	NUTqOmF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTFwOEexOVEh\|ryP	M{HteHNCVkeHUh?=
COLO-320-HSR	NYPBcnpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn25TWM2OD1zLki4NVk4KM7:TR?=	M4\2VnNCVkeHUh?=
HN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTFwOEi3NlUh\|ryP	NYTI[Gs1W0GQR1XS
HT	NUT2TXVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTFwOEi5OFch\|ryP	M2LKUnNCVkeHUh?=
LoVo	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVW0VFlbUUN3ME2xMlg6QDFizszN	NIHQRnVUSU6JRWK=
CGTH-W-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mke4TWM2OD1zLki5PVQ3KM7:TR?=	M3;1SnNCVkeHUh?=
NB6	NFzsPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nxe2lEPTB;MT65NVI6QCEQvF2=	MkW0V2FPT0WU
EW-22	NVGzZ3FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGixTWVKSzVyPUGuPVI5QDdizszN	MYrTRW5ITVJ?
ES6	M3TqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIThdnZKSzVyPUGuPVM3OzFizszN	NV3qNVFIW0GQR1XS
SCC-15	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXEUopKSzVyPUGuPVM5OTlizszN	MoGxV2FPT0WU
HL-60	MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHnempKSzVyPUGuPVM6ODJizszN	NF[w[XFUSU6JRWK=
human HOP-92	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFwOUSwOlUh\|ryP	NX\4OnZyW0GQR1XS
SW626	M3f3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XLWmlEPTB;MT65OFg6QSEQvF2=	NIq5PW9USU6JRWK=
HEC-1	NVnqU2o3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jvb2lEPTB;MT65OVM3KM7:TR?=	NY[4UGQ4W0GQR1XS
LB2241-RCC	Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTDTWM2OD1zLkm4NlMyKM7:TR?=	NHX4SW1USU6JRWK=
Ramos-2G6-4C10	M3;vXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTzTWM2OD1zLkm5OFk{KM7:TR?=	NUjSTFJOW0GQR1XS
A101D	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHDPY5jUUN3ME2yMlIxOzB\|IN88US=>	NH7OfXlUSU6JRWK=
NCI-H446	NILpbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPoU4VOUUN3ME2yMlA1PTl7IN88US=>	MYPTRW5ITVJ?
SBC-5	NXLaXWdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrPTWM2OD1{LkC2NVQ4KM7:TR?=	MVTTRW5ITVJ?
HOS	MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDEfmVKSzVyPUKuNFc3PTNizszN	M1XvcHNCVkeHUh?=
K5	M{joSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;MTWM2OD1{LkC3PFEyKM7:TR?=	NV7MTZhbW0GQR1XS
HLE	M2nWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LJTmlEPTB;Mj6wPFUzQSEQvF2=	M4DRWXNCVkeHUh?=
HSC-2	NWrtPIFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELmSldKSzVyPUKuNVI5QThizszN	M2Hh[HNCVkeHUh?=
LCLC-97TM1	M1jIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXNZ5RpUUN3ME2yMlE1PTh\|IN88US=>	MYDTRW5ITVJ?
DMS-273	Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTJwMUS4N\|ch\|ryP	MWPTRW5ITVJ?
TE-8	M4O2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVW5Z252UUN3ME2yMlE2PzZ3IN88US=>	MkLGV2FPT0WU
DSH1	NWDyUWl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTJwMU[zPVgh\|ryP	MUXTRW5ITVJ?
CAL-51	NGPQNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTJwMU[2PVkh\|ryP	NVv2SHJlW0GQR1XS
IST-SL1	NHPSRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXWTWM2OD1{LkG2PFQ1KM7:TR?=	NEDwcWtUSU6JRWK=
GCT	NGXwUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LOcmlEPTB;Mj6xO\|c4KM7:TR?=	Mo[0V2FPT0WU
SW948	Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILMOWhKSzVyPUKuNVg1PTZizszN	M2iySHNCVkeHUh?=
NOMO-1	NX:0SWpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzvTWM2OD1{LkG5N\|E4KM7:TR?=	NFe0eWlUSU6JRWK=
C8166	M2PxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TYc2lEPTB;Mj6yNVM{PCEQvF2=	MWrTRW5ITVJ?
OC-314	NXn4flZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXezVVBIUUN3ME2yMlI{OjV7IN88US=>	MljvV2FPT0WU
CAL-39	Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIf0e4hKSzVyPUKuNlM3OjZizszN	NHeyVWFUSU6JRWK=
MDA-MB-453	NYLDXZFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTJwMkSyO\|Uh\|ryP	NHG5Uo1USU6JRWK=
A673	NYniWYxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TOU2lEPTB;Mj6yOVg3OiEQvF2=	NEX4emxUSU6JRWK=
HTC-C3	MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PwTWlEPTB;Mj6yOlg2KM7:TR?=	MVLTRW5ITVJ?
NCI-H1666	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1r2UmlEPTB;Mj6yPFEyOSEQvF2=	NUmy[YZwW0GQR1XS
PSN1	NYPXZ\|NVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;CWmlEPTB;Mj6yPFkyOyEQvF2=	M4LvRXNCVkeHUh?=
GI-1	MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJwM{C1OFMh\|ryP	NYXFTIx{W0GQR1XS
HuH-7	MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEn6Xo1KSzVyPUKuN\|A3OzdizszN	MmnkV2FPT0WU
JAR	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTJwM{G5PFch\|ryP	NUfqWo97W0GQR1XS
5637	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILJXnBKSzVyPUKuN\|IyOjlizszN	NU\S[W51W0GQR1XS
GB-1	NEjVcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfQR\|NKSzVyPUKuN\|I{OzVizszN	MlnWV2FPT0WU
KP-N-YS	MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fETmlEPTB;Mj6zNlYyPSEQvF2=	MXvTRW5ITVJ?
OAW-42	M2m2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;NTWM2OD1{LkOzOFE3KM7:TR?=	NGHi[lJUSU6JRWK=
8-MG-BA	NHfmZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrsTWM2OD1{LkOzPVA3KM7:TR?=	M3S2NHNCVkeHUh?=
RH-18	NXXXNWZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\NTWM2OD1{LkO1NFIzKM7:TR?=	NWG2cJZ{W0GQR1XS
NCI-H1155	NV63bW9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XreWlEPTB;Mj6zOlczPSEQvF2=	NWrv[3hJW0GQR1XS
NB17	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLJNIFKSzVyPUKuN\|gzPDNizszN	Mmn3V2FPT0WU
NCI-H1437	M2PCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTJwNEG4O\|Mh\|ryP	MVvTRW5ITVJ?
SN12C	M1fPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHmW3lKSzVyPUKuOFMzOTRizszN	NVy3dW5PW0GQR1XS
HSC-3	NV7wNXY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDYeIw{UUN3ME2yMlQ1PTB7IN88US=>	NYjzXJdJW0GQR1XS
GAMG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnNToJlUUN3ME2yMlQ1PTZzIN88US=>	Ml3vV2FPT0WU
HT-1080	NUjmO5pTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInhNJZKSzVyPUKuOFQ5PjRizszN	MVfTRW5ITVJ?
A549	NWmzUVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PHeWlEPTB;Mj60OFg6OyEQvF2=	MYLTRW5ITVJ?
KNS-62	NVHKSnV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjtWFRKSzVyPUKuOFUxPjFizszN	NFjnSldUSU6JRWK=
YKG-1	NH3XS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2f3b2lEPTB;Mj60OVQ{PyEQvF2=	NYfOR5F1W0GQR1XS
LU-134-A	M{D2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJwNEewNFgh\|ryP	MW\TRW5ITVJ?
FADU	Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2[xWGlEPTB;Mj60O\|E3OiEQvF2=	NIrN[3lUSU6JRWK=
TGBC11TKB	NXvje\|VKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTJwNEexO\|ch\|ryP	NVjp[3RCW0GQR1XS
HT-3	NUHIWG1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfDWoxDUUN3ME2yMlQ6PTN3IN88US=>	MYTTRW5ITVJ?
NCI-H2170	NUC4[ol2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;tdWFKSzVyPUKuOVA2PDlizszN	NEj4TXhUSU6JRWK=
Mo-T	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTNTWM2OD1{LkWwPVI4KM7:TR?=	NV7u[HRHW0GQR1XS
CCRF-CEM	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEn0Vm1KSzVyPUKuOVMxPDNizszN	MoHpV2FPT0WU
KU-19-19	M2\BR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3G1c2lEPTB;Mj61N\|UyOyEQvF2=	MUnTRW5ITVJ?
NCI-H1048	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXKTWM2OD1{LkW1NFI2KM7:TR?=	NX;TdWxbW0GQR1XS
KOSC-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX:yTYNVUUN3ME2yMlU3ODd4IN88US=>	NYrNU4FkW0GQR1XS
A431	M{D1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXsTWM2OD1{LkW2N\|M2KM7:TR?=	MVHTRW5ITVJ?
COR-L23	M4fiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTJwNUi1OlYh\|ryP	MlnRV2FPT0WU
MKN28	NIjzfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\pTWM2OD1{LkW5NFM4KM7:TR?=	Ml3QV2FPT0WU
22RV1	NUDzSYV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTJwNUmyO\|Qh\|ryP	NHPoS45USU6JRWK=
ABC-1	M2XMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTMTWM2OD1{Lk[wOFYh\|ryP	MY\TRW5ITVJ?
NCI-H2126	M3L6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLhTWM2OD1{Lk[wPVg1KM7:TR?=	M4[1V3NCVkeHUh?=
DoTc2-4510	NXTYWXd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTJwNkKxPFUh\|ryP	NELFV\|BUSU6JRWK=
SCC-4	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nGTGlEPTB;Mj62N\|AyOiEQvF2=	NEDFfmNUSU6JRWK=
NCI-H661	M{jmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LLbWlEPTB;Mj62OFA5PSEQvF2=	MULTRW5ITVJ?
RPMI-2650	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\jcGtKSzVyPUKuOlQyPDNizszN	NFS5WFNUSU6JRWK=
NCI-H510A	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTJwNkS0NlYh\|ryP	NUfidJZiW0GQR1XS
BPH-1	NGjUZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTJwNkW4OUDPxE1?	NGTJ[ZZUSU6JRWK=
M14	NF7pTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTBd\|BjUUN3ME2yMlY3QTl\|IN88US=>	Ml;EV2FPT0WU
G-402	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXieVJKSzVyPUKuO\|A1PTFizszN	NGS3Tm5USU6JRWK=
AsPC-1	NYS4RZFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTiTWM2OD1{LkexNVch\|ryP	M2S1d3NCVkeHUh?=
NB12	NWjSWW57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJwN{G3NUDPxE1?	MVjTRW5ITVJ?
SK-HEP-1	M1j3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHxTWM2OD1{Lke0N\|kyKM7:TR?=	MlHjV2FPT0WU
U-266	NEX1UYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGKxeo1KSzVyPUKuO\|cyOjFizszN	MUjTRW5ITVJ?
AM-38	M3v3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnUZW1KSzVyPUKuO\|c{PTVizszN	NF6yeYFUSU6JRWK=
PC-14	NEXPZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rnUWlEPTB;Mj64NFUyKM7:TR?=	M1\CVnNCVkeHUh?=
EGI-1	NFTUNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjN[mtOUUN3ME2yMlgyPzR\|IN88US=>	NHHKPJFUSU6JRWK=
LS-411N	NYKyNlZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1z6UmlEPTB;Mj64NlM{KM7:TR?=	NHnuSlRUSU6JRWK=
BFTC-905	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXpTmpFUUN3ME2yMlg2PTJ\|IN88US=>	MofOV2FPT0WU
CaR-1	MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXTWZRKSzVyPUKuPFYh\|ryP	NVzsXZVSW0GQR1XS
NCI-H292	MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXkfYpKSzVyPUKuPFY2QTZizszN	M2jV[HNCVkeHUh?=
8305C	M3LhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLYTWM2OD1{Lki2OlQ2KM7:TR?=	MUjTRW5ITVJ?
SNU-449	M37WVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJwOEmxPFIh\|ryP	MUDTRW5ITVJ?
LCLC-103H	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELo[WRKSzVyPUKuPVA1OzhizszN	MV3TRW5ITVJ?
SW1573	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfRU3ZyUUN3ME2yMlk3ODh{IN88US=>	MWrTRW5ITVJ?
MLMA	M{K3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1v2UWlEPTB;Mj65OlcyPyEQvF2=	M4jJVnNCVkeHUh?=
NCI-H1355	NWrx[m9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrkTWM2OD1\|LkCwO\|k3KM7:TR?=	MULTRW5ITVJ?
RMG-I	NEjkR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTNwMEK1PVIh\|ryP	NH3z[odUSU6JRWK=
BB65-RCC	NWT3TGNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTNwMEOzNVQh\|ryP	Mk[5V2FPT0WU
PC-3	M3vDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTNwMEO4O\|Qh\|ryP	MnLIV2FPT0WU
SF268	MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTNwMES1NlMh\|ryP	MXTTRW5ITVJ?
NCI-H810	NGPYNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrxWpJvUUN3ME2zMlA1QDJ\|IN88US=>	M1\D[3NCVkeHUh?=
MEG-01	NGrQWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jkXGlEPTB;Mz6wOlE3PCEQvF2=	MmXTV2FPT0WU
SW13	NUXPWHJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF34dZRKSzVyPUOuNFc5PDdizszN	Mo\aV2FPT0WU
RH-1	Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3Rb\|R5UUN3ME2zMlExOjd6IN88US=>	MlHqV2FPT0WU
GT3TKB	MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTiTWM2OD1\|LkGxNlg{KM7:TR?=	MlTDV2FPT0WU
TK10	NGLlUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTNwMUO3NlQh\|ryP	MmHiV2FPT0WU
T-24	NHTzfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2r0S2lEPTB;Mz6xOVA4KM7:TR?=	MUHTRW5ITVJ?
A498	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnuOWt{UUN3ME2zMlIxQDdzIN88US=>	NEDiVGlUSU6JRWK=
GR-ST	NHPnXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3yzbmlEPTB;Mz6yNlE{QSEQvF2=	NYW1[XBsW0GQR1XS
LB2518-MEL	M4KwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTRTWM2OD1\|LkKyN\|k5KM7:TR?=	NUHuSGNJW0GQR1XS
T47D	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTNwMkO2Nlch\|ryP	MoryV2FPT0WU
NCI-H1651	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfJ[VhKSzVyPUOuNlQ3PDRizszN	NF:2NHpUSU6JRWK=
EC-GI-10	MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV75RZdCUUN3ME2zMlI3OTV\|IN88US=>	M4TWdXNCVkeHUh?=
HT-29	NWLiTWQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTNwMk[2NVQh\|ryP	NH\MVpNUSU6JRWK=
GI-ME-N	Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\ySWltUUN3ME2zMlI6PTFzIN88US=>	NE\xc2tUSU6JRWK=
SW756	M1PxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M16yfWlEPTB;Mz6yPVYzQSEQvF2=	Mn3yV2FPT0WU
RKO	M1XJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3G5V2lEPTB;Mz6zNFc2PyEQvF2=	NWXZVmFtW0GQR1XS
NCI-H1563	NYK4XoJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLVZnBMUUN3ME2zMlM{ODF6IN88US=>	NHfRZ3dUSU6JRWK=
DJM-1	M1zWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTNwM{e2O\|Qh\|ryP	MUDTRW5ITVJ?
L-428	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{[2fGlEPTB;Mz60NFA1PSEQvF2=	M3fKfXNCVkeHUh?=
NCI-H2122	NFzjRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYmzNXd6UUN3ME2zMlQyOzF{IN88US=>	NFzmR2RUSU6JRWK=
Ca-Ski	M3PtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jRZmlEPTB;Mz60OVQ{KM7:TR?=	M3zHe3NCVkeHUh?=
639-V	NF\DXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;tUldKSzVyPUOuOFYxPTdizszN	NGHIXlRUSU6JRWK=
SW1116	M3HBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTNwNE[yOlkh\|ryP	NW\4dYRtW0GQR1XS
DMS-114	NWDi[nU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDrW5B7UUN3ME2zMlQ4ODZ4IN88US=>	NVXEbFY4W0GQR1XS
MZ2-MEL	NI\hXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXwTWM2OD1\|LkS3OlgyKM7:TR?=	M4C3OHNCVkeHUh?=
COLO-829	NFu4VHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTFTWM2OD1\|LkWwNFc{KM7:TR?=	M1nV[XNCVkeHUh?=
J82	NIC1WYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fyU2lEPTB;Mz61NFU4KM7:TR?=	NXruO3pVW0GQR1XS
EW-13	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPGWlVKSzVyPUOuOVI2OSEQvF2=	MUTTRW5ITVJ?
RXF393	NFv5bpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7kTWM2OD1\|LkWzNlk1KM7:TR?=	MnjLV2FPT0WU
CAL-62	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\aTWM2OD1\|LkW0OVE1KM7:TR?=	NFfOPXBUSU6JRWK=
OCUB-M	M2W2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnMNmVKSzVyPUOuOVQ3PjVizszN	MYjTRW5ITVJ?
BT-474	M17MOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LUNWlEPTB;Mz62N\|MyKM7:TR?=	NIrPNoRUSU6JRWK=
KYSE-180	MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTQendEUUN3ME2zMlY{Ozd{IN88US=>	NX\J[JBnW0GQR1XS
NCI-H650	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknMTWM2OD1\|Lk[0Nlg4KM7:TR?=	MnjpV2FPT0WU
Detroit562	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHqxV41KSzVyPUOuOlUxOjJizszN	M1XMS3NCVkeHUh?=
SW48	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;PTWM2OD1\|Lk[1OlU4KM7:TR?=	NILHZmJUSU6JRWK=
KYSE-450	NUD6d3FST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTNwNki1PFIh\|ryP	M2ezPXNCVkeHUh?=
KYSE-510	M{jKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTNwN{KxPFEh\|ryP	MUjTRW5ITVJ?
GP5d	M3HGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGf0eYJKSzVyPUOuO\|I6PSEQvF2=	NWS5TGpDW0GQR1XS
RPMI-7951	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTYdoY4UUN3ME2zMlc1PzJ\|IN88US=>	NFTCRY1USU6JRWK=
Becker	M4npR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTNwN{WwNVIh\|ryP	MXXTRW5ITVJ?
WM-115	NGTNNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPmTWM2OD1\|Lke4NVk2KM7:TR?=	NGqxV2RUSU6JRWK=
G-401	MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILrdYtKSzVyPUOuO\|kxQDVizszN	M3fwenNCVkeHUh?=
PANC-08-13	NXjG[Ww{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\ZXVdCUUN3ME2zMlc6PjB{IN88US=>	MYDTRW5ITVJ?
SW982	NH\kRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfY[41KSzVyPUOuPFA2PTFizszN	MnHQV2FPT0WU
D-263MG	M1PqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTNwOEKwOVEh\|ryP	MYPTRW5ITVJ?
KM-H2	Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULrbIFWUUN3ME2zMlgzPjJ2IN88US=>	NIXvWIxUSU6JRWK=
SK-MEL-3	M1vzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonMTWM2OD1\|LkiyPFQyKM7:TR?=	NUTBRY9lW0GQR1XS
NCI-H1581	M{PGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDuTHdXUUN3ME2zMlg1PDh6IN88US=>	MUnTRW5ITVJ?
LS-123	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jPVWlEPTB;Mz64O\|kxQSEQvF2=	MoPOV2FPT0WU
CAKI-1	NXTPdYlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{W3WWlEPTB;Mz64PVA2OiEQvF2=	MnLvV2FPT0WU
MEL-JUSO	NX3wemw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\JcFBpUUN3ME2zMlg6OTV\|IN88US=>	NHPXd\|FUSU6JRWK=
HCE-4	NEL6UopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTNwOUG2OlMh\|ryP	NXvJNZdKW0GQR1XS
TE-10	M1XUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTNwOUKwNUDPxE1?	M3jFVXNCVkeHUh?=
OVCAR-4	MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfoTWM2OD1\|LkmyPFg6KM7:TR?=	M1uwS3NCVkeHUh?=
ETK-1	M1vBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlP6TWM2OD1\|Lkm0OlM2KM7:TR?=	NYLPN4xtW0GQR1XS
A2780	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljCTWM2OD12LkC1PVY3KM7:TR?=	NIrkXGtUSU6JRWK=
LU-65	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1q2N2lEPTB;ND6wO\|Y{OyEQvF2=	MoryV2FPT0WU
BHY	Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XM[WlEPTB;ND6xNlQ6PSEQvF2=	NWnsfIpkW0GQR1XS
COR-L105	NETkfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mly3TWM2OD12LkGzNFUyKM7:TR?=	NGDoe5JUSU6JRWK=
CAL-12T	NVTKO3UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnT0TWM2OD12LkGzNVA{KM7:TR?=	NWTEZW1HW0GQR1XS
SCH	NWHOOmI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmD4TWM2OD12LkG1O\|Q{KM7:TR?=	MX7TRW5ITVJ?
CW-2	M1frUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTRwMUmwNFEh\|ryP	MV3TRW5ITVJ?
HCC1806	NXLVNoxCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVH2[3RnUUN3ME20MlIxOzF{IN88US=>	NFLoNGZUSU6JRWK=
KP-N-YN	NXnJ[YJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIP6PJpKSzVyPUSuNlA6OjdizszN	NUXKZZV{W0GQR1XS
T98G	M1OzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nkN2lEPTB;ND6yNlE2PyEQvF2=	MkDYV2FPT0WU
CAL-54	NIToXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInqXYVKSzVyPUSuNlI{QDFizszN	MWTTRW5ITVJ?
CAL-33	NFTDO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\HVINKSzVyPUSuNlMxPjRizszN	NHHCbohUSU6JRWK=
SNU-C2B	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnaS4tEUUN3ME20MlI1PzZ7IN88US=>	M1nUfnNCVkeHUh?=
NUGC-3	NV3tSoZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3H5OGlEPTB;ND6yOVUxPSEQvF2=	NXrWPIlzW0GQR1XS
DOK	NF[wb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTRwMk[1PVMh\|ryP	MXLTRW5ITVJ?
MMAC-SF	M{PSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnGyTWM2OD12LkK2PFU6KM7:TR?=	NVzkT2k1W0GQR1XS
KYSE-70	M1;wPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvsTWM2OD12LkK5N\|Qh\|ryP	NFy4PIlUSU6JRWK=
A204	NH3XfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTRwM{W4NFMh\|ryP	M4fjUnNCVkeHUh?=
SCC-25	NX7mdJdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWi2dpR7UUN3ME20MlM2QDF7IN88US=>	M4T6bHNCVkeHUh?=
EPLC-272H	NGXmUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTRwM{i5OUDPxE1?	NIn6VWdUSU6JRWK=
CAL-120	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrWNY84UUN3ME20MlM5QTl{IN88US=>	NVru[GFwW0GQR1XS
LS-513	NIDBbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTRwNEKxPVgh\|ryP	NFXGNlRUSU6JRWK=
CAPAN-1	NYX2OVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTRwNEKzPFIh\|ryP	M4PrXHNCVkeHUh?=
ESS-1	NHnSTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTRwNEK3NlQh\|ryP	M2rUPXNCVkeHUh?=
GMS-10	NWLQe4E3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTRwNEK4NVkh\|ryP	NGr4ZYRUSU6JRWK=
NCI-N87	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTwSpRxUUN3ME20MlUxQDZ6IN88US=>	Mk\jV2FPT0WU
HMV-II	NXPkS3RIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHjTWM2OD12LkWxO\|Mh\|ryP	NETUTWJUSU6JRWK=
COLO-741	M17rSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmn5TWM2OD12LkW1PVk1KM7:TR?=	NFXRZVRUSU6JRWK=
MKN45	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDtN3hKUUN3ME20MlU4PzN{IN88US=>	NYDaPGZmW0GQR1XS
OAW-28	NGjaU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTRwNUizPVgh\|ryP	NYDC[nRpW0GQR1XS
OCI-AML2	MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTRwNkWyN\|gh\|ryP	NH\tS45USU6JRWK=
MDA-MB-231	M3vp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XTNWlEPTB;ND63NFI1OyEQvF2=	NGTNU\|VUSU6JRWK=
NCI-H1648	M{Dp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTRwN{KyO\|Mh\|ryP	M4HZOXNCVkeHUh?=
NCI-H1792	MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTRwN{[xNFch\|ryP	M2jre3NCVkeHUh?=
GCIY	MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnHblltUUN3ME20Mlc4PDJ2IN88US=>	MoTkV2FPT0WU
Hs-578-T	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfYPFRKSzVyPUSuO\|c3PTVizszN	MYPTRW5ITVJ?
SW962	NGHoUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTRwN{iwNVEh\|ryP	NUT4eGJjW0GQR1XS
NCI-H630	NGnDUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHWxWpRKSzVyPUSuO\|gxQDFizszN	MoXuV2FPT0WU
786-0	MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTXTWM2OD12Lke4O\|c{KM7:TR?=	NUjLb5htW0GQR1XS
FTC-133	NXf4RlJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTRwN{myOlMh\|ryP	NVK0SVRCW0GQR1XS
BT-20	M1\YNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NED6N4pKSzVyPUSuO\|k1OjlizszN	MljGV2FPT0WU
Mewo	NELvXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\qSpY4UUN3ME20MlgyPzR5IN88US=>	NUjMVWJtW0GQR1XS
SW780	M4DaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\hTWM2OD12Lki1O\|Y3KM7:TR?=	MU\TRW5ITVJ?
OE33	M2fDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTRwOEe3NVMh\|ryP	MWTTRW5ITVJ?
HCC1569	NXLXbY5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mne1TWM2OD12Lki4OFU5KM7:TR?=	NWfOUmpVW0GQR1XS
TE-6	NGXYZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\2dFNKSzVyPUSuPVM6PzdizszN	NHjwWnRUSU6JRWK=
SK-N-FI	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfEcWs4UUN3ME20Mlk1PDJzIN88US=>	NWrDfG96W0GQR1XS
PANC-03-27	NHLtemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTRwOUm5OlIh\|ryP	NWrHfHF1W0GQR1XS
MCF7	NE\zbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTVwMEC3N\|gh\|ryP	MXfTRW5ITVJ?
UACC-257	NFTzeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3ez[GlEPTB;NT6wNlg1PSEQvF2=	NXjMVJhuW0GQR1XS
SW1088	M4izdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnlXpBKSzVyPUWuNFI6PDRizszN	NFrqOHBUSU6JRWK=
A704	MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHn1d4lKSzVyPUWuNFMxPiEQvF2=	NILyZVVUSU6JRWK=
A2058	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4i5RmlEPTB;NT6wOVkxQCEQvF2=	MlyzV2FPT0WU
Calu-3	NVfPSVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVe1dY1lUUN3ME21MlA3PDV{IN88US=>	MlKzV2FPT0WU
RERF-LC-MS	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDkV2JKSzVyPUWuNFY6ODNizszN	NHHKTGlUSU6JRWK=
AU565	NIC3UHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTVwMEm3NFIh\|ryP	NIrubphUSU6JRWK=
DMS-79	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;MSIVKSzVyPUWuNVM5QDNizszN	NU\SSlhvW0GQR1XS
DK-MG	NIHM[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfMPIVKSzVyPUWuNVg1OzhizszN	M1nKT3NCVkeHUh?=
HuCCT1	MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIWyeVBKSzVyPUWuNlM5PTZizszN	NULndoc3W0GQR1XS
HT-144	NUftVWtwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTVwMkS5PFch\|ryP	MYDTRW5ITVJ?
M059J	Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Trb2lEPTB;NT6yOVc3KM7:TR?=	NILMSnFUSU6JRWK=
COLO-792	NWDKUJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoH2TWM2OD13LkK2N\|U3KM7:TR?=	NEToWXZUSU6JRWK=
SF539	NX7E[mtYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDDTWM2OD13LkK2OlMzKM7:TR?=	MYLTRW5ITVJ?
SK-UT-1	NETlOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHGx[29KSzVyPUWuNlc4PTFizszN	MX3TRW5ITVJ?
NCI-H1703	MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHsVmNKSzVyPUWuN\|U5OjZizszN	NHLG[G1USU6JRWK=
SW837	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDxVmpVUUN3ME21MlM4QDd6IN88US=>	NWP2doxIW0GQR1XS
U251	NIHLRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLPTWM2OD13LkO5NFk3KM7:TR?=	MnSxV2FPT0WU
SW1710	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTVwNEG1OVQh\|ryP	NH3rZWtUSU6JRWK=
NCI-H1299	NGrxWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnIc3hKSzVyPUWuOFY{OzVizszN	MkXHV2FPT0WU
RVH-421	M3\5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\iTVNKSzVyPUWuOFk6ODhizszN	NUXnOYg4W0GQR1XS
UM-UC-3	NGn4fIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PVXmlEPTB;NT62NlY2OSEQvF2=	M13xd3NCVkeHUh?=
MDA-MB-175-VII	NH:0R4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rlSWlEPTB;NT62OFA1OSEQvF2=	NGixOmFUSU6JRWK=
KYSE-270	NF6yeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzqVnhoUUN3ME21MlY3ODNzIN88US=>	MkPTV2FPT0WU
COLO-668	MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjOemtKSzVyPUWuO\|E{OiEQvF2=	MnG5V2FPT0WU
LN-405	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfNb2hKSzVyPUWuO\|MxQDVizszN	NY\BcIJlW0GQR1XS
HT-1376	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvTTWM2OD13Lke4NFUzKM7:TR?=	MYHTRW5ITVJ?
769-P	MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVroenozUUN3ME21Mlg3PzF6IN88US=>	M3T0eXNCVkeHUh?=
HuP-T3	NHLuSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzFU5Q4UUN3ME21Mlg5Pjd5IN88US=>	NULGUXFDW0GQR1XS
MDA-MB-415	NF\1SVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTVwOUKxN\|kh\|ryP	NYmxZWhyW0GQR1XS
MKN7	MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DMfGlEPTB;NT65PFgh\|ryP	MkDqV2FPT0WU
KS-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M131R2lEPTB;NT65PFg{PiEQvF2=	M3HuNXNCVkeHUh?=
647-V	MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTVwOUmxOFgh\|ryP	NXPOUXE3W0GQR1XS
COLO-679	NHnSeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDvOGlKUUN3ME22MlAxOjV3IN88US=>	NXPndGxOW0GQR1XS
AN3-CA	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH:3PVRKSzVyPU[uNFM1PDFizszN	NUG4eZR7W0GQR1XS
C32	NG\QdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXx[G9KSzVyPU[uNVMxOzRizszN	NF\yS25USU6JRWK=
KM12	Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTZwMkSwPVkh\|ryP	NWHiXIZmW0GQR1XS
KINGS-1	NYq0UW1OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\PTWM2OD14LkK2NVUzKM7:TR?=	NHLkfmhUSU6JRWK=
KYSE-410	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXaVFhxUUN3ME22MlMxPjR3IN88US=>	M1vYdnNCVkeHUh?=
HPAF-II	NIS4d5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTZwM{W0PEDPxE1?	MX\TRW5ITVJ?
LAN-6	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfie\|VxUUN3ME22MlQ6PjNzIN88US=>	M3XUTXNCVkeHUh?=
LU-99A	NFq1eVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fp[2lEPTB;Nj61OVk5QSEQvF2=	MYLTRW5ITVJ?
SJSA-1	NFjY[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUKz[Gt5UUN3ME22MlU3OzR5IN88US=>	MX\TRW5ITVJ?
MSTO-211H	NVPqbXN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkO1TWM2OD14LkeyNlM{KM7:TR?=	MkHmV2FPT0WU
SW900	NFLV[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjOS2I5UUN3ME22Mlc3OjJzIN88US=>	M1[ybnNCVkeHUh?=
LNCaP-Clone-FGC	NWf6S3FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zWe2lEPTB;Nj64NFQxOyEQvF2=	NYrxbpUyW0GQR1XS
OMC-1	Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3NTFJvUUN3ME22Mlg2PDB{IN88US=>	Mm\xV2FPT0WU
IST-MEL1	NWrmclQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnuepVWUUN3ME22Mlg6PjZ7IN88US=>	NFHBZ2JUSU6JRWK=
TE-9	NIDkVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETCdJBKSzVyPU[uPFk5PDdizszN	NXHjd2dIW0GQR1XS
NCI-H2030	NFvlPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUL3NolEUUN3ME22MlkyOjJ4IN88US=>	M4\H[HNCVkeHUh?=
BFTC-909	Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTdwMEC2OFEh\|ryP	NX7C[4F3W0GQR1XS
NCI-SNU-5	M{HLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fXXGlEPTB;Nz6wNlE2QSEQvF2=	NYXoTpB{W0GQR1XS
TE-5	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\wOlRKSzVyPUeuNFI5QDFizszN	NInoPZdUSU6JRWK=
SK-MES-1	NWrBWVNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTdwMEW0Nlch\|ryP	MX3TRW5ITVJ?
SHP-77	NIrBXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTdwMUO5OVIh\|ryP	MV3TRW5ITVJ?
NCI-H1623	M17MRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHpO\|BKSzVyPUeuNVQxPzJizszN	MkPIV2FPT0WU
TE-11	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILnVWFKSzVyPUeuNVUyQDRizszN	MXLTRW5ITVJ?
EKVX	M3vN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\uVmlKSzVyPUeuNVkzPjdizszN	NXPxcZVqW0GQR1XS
OVCAR-3	NFvBNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTdwMkGxN\|Mh\|ryP	NEDmTXFUSU6JRWK=
C3A	NUmw[VJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mly1TWM2OD15LkO0OVIh\|ryP	Mn3rV2FPT0WU
CFPAC-1	NEPRcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmD5TWM2OD15LkO2NlIzKM7:TR?=	NYnDSplvW0GQR1XS
MG-63	NYLnTJFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LKVmlEPTB;Nz60NVg1QSEQvF2=	NIDpd4NUSU6JRWK=
KYSE-140	NXfte2FKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTdwNESwOlEh\|ryP	NH7HVW1USU6JRWK=
MPP-89	NXnyfVhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWSwe5J3UUN3ME23MlU6PzJ7IN88US=>	NHTXdnhUSU6JRWK=
COLO-824	NXX1T3RqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LCUmlEPTB;Nz63Nlg3OyEQvF2=	NF;rOVhUSU6JRWK=
SiHa	MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1z6cWlEPTB;Nz64N\|cxPyEQvF2=	Mnr4V2FPT0WU
SNU-387	NUX1bHVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTqXZJQUUN3ME23Mlg2OzR5IN88US=>	NFLMUJNUSU6JRWK=
A172	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWP5dJpCUUN3ME23Mlg3OTd{IN88US=>	MnnPV2FPT0WU
COLO-680N	NIOzRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzFTWM2OD15LkmxO\|Mh\|ryP	NGD2UWVUSU6JRWK=
HCC1395	NEXP[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fzWmlEPTB;OD6wOVQ2OiEQvF2=	NXLIOm1GW0GQR1XS
NCI-H28	NFjybFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jKTmlEPTB;OD6wOVk3OyEQvF2=	MmrzV2FPT0WU
LC-2-ad	MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33id2lEPTB;OD6yNVk{PyEQvF2=	MYfTRW5ITVJ?
S-117	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRThwMkWzOVMh\|ryP	NED4NpVUSU6JRWK=
NCI-H1838	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvNTWM2OD16LkK1O\|gyKM7:TR?=	NIHn[oZUSU6JRWK=
PANC-10-05	NXzKV2ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7JU\|BKSzVyPUiuN\|cxPDdizszN	MUnTRW5ITVJ?
KALS-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTRTWM2OD16LkWwPVI5KM7:TR?=	NGjrcYxUSU6JRWK=
LS-1034	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXITWM2OD16LkW3OFM4KM7:TR?=	M37LdXNCVkeHUh?=
TGBC1TKB	M{f3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRThwN{O1N\|Uh\|ryP	MUTTRW5ITVJ?
OE19	M3u0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGC4WWpKSzVyPUiuO\|YzPjJizszN	MXHTRW5ITVJ?
D-502MG	NFm1S4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRThwN{[5PVQh\|ryP	M3nNbnNCVkeHUh?=
JEG-3	NYLDT4UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DJT2lEPTB;OD63PFYyQCEQvF2=	MlvvV2FPT0WU
DBTRG-05MG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPKTJlKSzVyPUiuPFc2PjVizszN	MoS0V2FPT0WU
ME-180	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIW1UHBKSzVyPUmuNFY4OjVizszN	NHq4dpdUSU6JRWK=
NCI-H1573	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M171eWlEPTB;OT6xNFU{OiEQvF2=	Mni1V2FPT0WU
HCC2998	M{L5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vKZWlEPTB;OT6xN\|Y5OSEQvF2=	MXrTRW5ITVJ?
ACHN	NYLPSnZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDPbWFKSzVyPUmuNlQ6PzVizszN	MYXTRW5ITVJ?
D-392MG	NGC5fG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXK3bG1EUUN3ME25MlI2PzF3IN88US=>	M{e4ZXNCVkeHUh?=
no-11	NUTsUVVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTlwMk[wNlgh\|ryP	M13ndnNCVkeHUh?=
KLE	NGTX[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfMTWM2OD17LkOyNlMzKM7:TR?=	NXf4OnUyW0GQR1XS
Calu-6	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPJVJBRUUN3ME25MlM4PTJ6IN88US=>	M1:5c3NCVkeHUh?=
LB831-BLC	NWLyUHRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTlwNEWxO\|Eh\|ryP	MoDhV2FPT0WU
SW684	M1TZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnITWM2OD17LkS2NVE3KM7:TR?=	MYrTRW5ITVJ?
SH-4	M37YTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknTTWM2OD17LkS5N\|Y1KM7:TR?=	MWTTRW5ITVJ?
IST-MES1	NWfOU2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jhbmlEPTB;OT61NVY1PCEQvF2=	NGWxSlBUSU6JRWK=
Saos-2	NIK2fHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXS1PYlwUUN3ME25MlUzOTl3IN88US=>	MUfTRW5ITVJ?
NCI-H2087	MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHpTWM2OD17Lk[3N\|UzKM7:TR?=	MY\TRW5ITVJ?
SCC-9	M2TkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTlwN{G4NVYh\|ryP	NEDKbWNUSU6JRWK=
MFE-280	NGf6TmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHoZVhKSzVyPUmuO\|I4QDVizszN	NW\wUnd{W0GQR1XS
BEN	M2n2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFWwbWJKSzVyPUmuPFIyPTlizszN	M4LwNHNCVkeHUh?=
CP50-MEL-B	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTlwOUK0N\|Ih\|ryP	NUjSTohPW0GQR1XS
SK-MEL-28	NF\a[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTFyLkCxPVMh\|ryP	M{fpT3NCVkeHUh?=
NCI-H2452	M{n2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4flZmlEPTB;MUCuNVYh\|ryP	MlTEV2FPT0WU
NCI-H1395	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrKb\|RKSzVyPUGwMlE4QCEQvF2=	NYnKSVVGW0GQR1XS
NCI-H2052	NF\PUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\CTWM2OD1zMD6xPFgzKM7:TR?=	NHu0fnFUSU6JRWK=
A375	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnRfWFKSzVyPUGwMlI1PTJizszN	MnS1V2FPT0WU
HCC38	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlexTWM2OD1zMD6zNlIh\|ryP	MkWzV2FPT0WU
LK-2	M3fGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe3e\|JKSzVyPUGwMlQzODhizszN	M2jGNnNCVkeHUh?=
SF126	M2TXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvTW21CUUN3ME2xNE41PzJ5IN88US=>	M13HV3NCVkeHUh?=
SK-MEL-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWL3WW9xUUN3ME2xNE44QDN6IN88US=>	M1WyUHNCVkeHUh?=
ACN	M1XjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTFyLki2O\|kh\|ryP	Ml65V2FPT0WU
BB30-HNC	NIXGWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\SSGlEPTB;MUCuPFcyOSEQvF2=	Moe4V2FPT0WU
NCI-H747	M3zwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYX1dYlwUUN3ME2xNE45PzR4IN88US=>	NULKUpBLW0GQR1XS
KYSE-150	NXTRNYRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVqyRWhvUUN3ME2xNU4xOzh5IN88US=>	NVXyfXdUW0GQR1XS
D-247MG	NYS2bHhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXRc5hKSzVyPUGxMlExODlizszN	MnPOV2FPT0WU
BxPC-3	NWPkZ413T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moj6TWM2OD1zMT6zO\|Q4KM7:TR?=	M2PrenNCVkeHUh?=
SK-MEL-30	M4rtbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nuXWlEPTB;MUGuOFA4QSEQvF2=	MXnTRW5ITVJ?
CAS-1	MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTFzLkSxNFkh\|ryP	MojEV2FPT0WU
no-10	M4TuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTyTWM2OD1zMj6xNlE4KM7:TR?=	MnLxV2FPT0WU
NCI-H2405	MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVj1VG5nUUN3ME2xNk4zODN4IN88US=>	NInOdJlUSU6JRWK=
KGN	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYn2WmhTUUN3ME2xNk4zQTBzIN88US=>	M{HuTnNCVkeHUh?=
BB49-HNC	NELMNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTFO2pwUUN3ME2xNk4{QTV4IN88US=>	MY\TRW5ITVJ?
NCI-H1693	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1Lhb2lEPTB;MUKuOVgyPiEQvF2=	NV;uPXZOW0GQR1XS
RO82-W-1	NUH4UY1iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPPTWM2OD1zMz6wOlQ6KM7:TR?=	NG\wPIdUSU6JRWK=
CAL-85-1	Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4ntSWlEPTB;MUOuOFM6QSEQvF2=	M3TNfXNCVkeHUh?=
H-EMC-SS	Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LoVGlEPTB;MUOuPVExPCEQvF2=	MoLMV2FPT0WU
SW1783	M3zPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYK1[4g6UUN3ME2xOE4zOzlzIN88US=>	MmX4V2FPT0WU
LB771-HNC	NIHPd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTF2LkSxPUDPxE1?	Mm\xV2FPT0WU
HCC70	NUjITJVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlKyTWM2OD1zND60NlM{KM7:TR?=	M1r4[nNCVkeHUh?=
KNS-81-FD	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;NNXZKSzVyPUG0MlcxPDVizszN	NWGz[Ho1W0GQR1XS
KYSE-520	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTF2LkmyO{DPxE1?	M3LNVHNCVkeHUh?=
TGBC24TKB	MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jodGlEPTB;MUSuPVU{QSEQvF2=	M1XlbXNCVkeHUh?=
SNB75	NIXaNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPWTWM2OD1zNT6wO\|I6KM7:TR?=	MoDsV2FPT0WU
SW872	NWPOfItZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTF3LkKyNVgh\|ryP	M3vTNXNCVkeHUh?=
U031	M4q3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn6yTWM2OD1zNT64NFI5KM7:TR?=	M3Ly[3NCVkeHUh?=
ChaGo-K-1	M1LZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jmNGlEPTB;MUWuPFM2QSEQvF2=	MkXFV2FPT0WU
NCI-H441	MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofXTWM2OD1zNj6wNFM6KM7:TR?=	NVHndoZTW0GQR1XS
TE-12	NXmzbVBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHQXWpKSzVyPUG2MlE5PzNizszN	NVPu[pJmW0GQR1XS
NCI-H1755	M17p[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3KXJdKSzVyPUG2MlU4OyEQvF2=	M2i3UnNCVkeHUh?=
KNS-42	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33tNWlEPTB;MU[uOlU5QSEQvF2=	NXrRS2xxW0GQR1XS
SK-PN-DW	M{TzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTF5LkSyNFEh\|ryP	NFeyWlZUSU6JRWK=
NCI-H226	NUT3XoZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXNTWM2OD1zNz65N\|Q2KM7:TR?=	NEK5Z2lUSU6JRWK=
K-562	M2fyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTF6Lk[zNVch\|ryP	M{PWe3NCVkeHUh?=
A388	M1HrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEW3RZVKSzVyPUG5MlA{ODNizszN	M4DtV3NCVkeHUh?=
ZR-75-30	M4XSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLtTWM2OD1zOT6wPVY5KM7:TR?=	M2Ti[nNCVkeHUh?=
LU-135	Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPPd2JDUUN3ME2xPU4zPjN4IN88US=>	MnT3V2FPT0WU
NCI-H2029	M4nZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjCe5VQUUN3ME2xPU43ODJzIN88US=>	MWTTRW5ITVJ?
HT-1197	NWfjc2RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTF7LkmyNlch\|ryP	M2HHdnNCVkeHUh?=
IGR-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFv5Sm5KSzVyPUKwMlMyOTdizszN	MmrVV2FPT0WU
U-87-MG	Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fWXWlEPTB;MkCuOlQyOyEQvF2=	MoDQV2FPT0WU
NCI-H1304	M4fMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPRTWM2OD1{MD63OVAyKM7:TR?=	NInuZnlUSU6JRWK=
RCC10RGB	NEDWXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jBVGlEPTB;MkGuNlgzQSEQvF2=	M1TsOnNCVkeHUh?=
NCI-H520	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJ{Lke2NVEh\|ryP	MVfTRW5ITVJ?
SK-LU-1	MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDheJhKSzVyPUKzMlA4OThizszN	Mm\PV2FPT0WU
UACC-893	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7X[GxMUUN3ME2yN{4yODN6IN88US=>	NY\BTHJwW0GQR1XS
NCI-H2347	NI\ufopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTJ\|LkK2O\|Qh\|ryP	NVT3cIF7W0GQR1XS
U-118-MG	M2riTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXqTWM2OD1{Mz63NlE4KM7:TR?=	MmOyV2FPT0WU
NCI-H596	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjINHZZUUN3ME2yN{46ODV3IN88US=>	NWTXUnM2W0GQR1XS
MZ1-PC	NH3OTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jMOGlEPTB;MkSuOlc2QSEQvF2=	NFnYTWdUSU6JRWK=
SW1417	M{jtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrzT4FJUUN3ME2yOU4zPDl6IN88US=>	NYXjTXY4W0GQR1XS
NCI-H82	NYDWOWZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfrc4gyUUN3ME2yOk41Ojh6IN88US=>	NH2xVmtUSU6JRWK=
COLO-678	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTJ5LkS5NVkh\|ryP	MmrQV2FPT0WU
KURAMOCHI	NH3Pe\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{L1[mlEPTB;MkiuNVI3KM7:TR?=	MUPTRW5ITVJ?
NCI-H1650	NFnxeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7YTWM2OD1\|MD6xPVI1KM7:TR?=	MnO2V2FPT0WU
HCC1954	NEGwUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTNzLkO2OlYh\|ryP	M1HZfnNCVkeHUh?=
GAK	MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\tNmlEPTB;M{KuNlYyPiEQvF2=	MoPiV2FPT0WU
YAPC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;4fXFKSzVyPUOzMlc3PDhizszN	NX\wS5pFW0GQR1XS
NCI-H2228	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\tTWM2OD1\|ND6zOlA2KM7:TR?=	NIPhPIdUSU6JRWK=
VMRC-RCZ	M1f5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTN4LkOwNlIh\|ryP	NEXDRVlUSU6JRWK=
NMC-G1	M1ewTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzYTWM2OD1\|Nz6wOVI6KM7:TR?=	MmnUV2FPT0WU
D-336MG	MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTFOZl2UUN3ME20NU45PDR{IN88US=>	Ml7JV2FPT0WU
UACC-62	M3\aWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XQR2lEPTB;NEKuOVUxPSEQvF2=	NFXwOYNUSU6JRWK=
C-33-A	NHPQb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTR3LkOyOVYh\|ryP	NIfnPYVUSU6JRWK=
HCC1937	MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLOZVNKSzVyPUS3MlE6PThizszN	Mn;UV2FPT0WU
HDLM-2	NIHvb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\DTWM2OD12Nz6yNlg4KM7:TR?=	Mn\PV2FPT0WU
NCI-H727	M1vQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTR5LkK0OVEh\|ryP	NHzyS45USU6JRWK=
NY	M{\0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELqUFhKSzVyPUS5MlM6ODhizszN	MlzWV2FPT0WU
NCI-H2291	M2PMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjJ[oNKSzVyPUS5Mlg{ODFizszN	M{mxd3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	+ Expand Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	+ Expand Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	+ Expand Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Formulation: Dissolved in DMSO Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01281176	Active not recruiting	Adult Solid Neoplasm	National Cancer Institute (NCI)	February 9 2011	Phase 1
NCT01189266	Active not recruiting	Anaplastic Astrocytoma\|Anaplastic Oligoastrocytoma\|Brain Stem Glioma\|Childhood Glioblastoma\|Giant Cell Glioblastoma\|Gliosarcoma\|Untreated Childhood Anaplastic Astrocytoma\|Untreated Childhood Anaplastic Oligoastrocytoma\|Untreated Childhood Brain Stem Glioma\|Untreated Childhood Giant Cell Glioblastoma\|Untreated Childhood Gliosarcoma	National Cancer Institute (NCI)	August 9 2010	Phase 1\|Phase 2
NCT00703664	Completed	Recurrent Mantle Cell Lymphoma\|Recurrent Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	July 9 2008	Phase 2
NCT03198559	Suspended	HIV Infections	The Peter Doherty Institute for Infection and Immunity\|Merck Sharp & Dohme Corp.\|The Alfred\|University of Melbourne	August 8 2017	Phase 1\|Phase 2
NCT02538510	Active not recruiting	Head and Neck Squamous Cell Carcinoma\|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Recurrent Nasopharynx Carcinoma\|Recurrent Salivary Gland Carcinoma\|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary\|Stage III Major Salivary Gland Carcinoma\|Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Stage III Nasopharyngeal Carcinoma\|Stage IV Nasopharyngeal Carcinoma\|Stage IVA Major Salivary Gland Carcinoma\|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Stage IVB Major Salivary Gland Carcinoma\|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Stage IVC Major Salivary Gland Carcinoma\|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma	University of Washington\|National Cancer Institute (NCI)	October 8 2015	Phase 1\|Phase 2
NCT01983969	Completed	Advanced Cancers\|Lymphoma	M.D. Anderson Cancer Center	November 7 2013	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
4SC-202 ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 100 Publications

20 Customer Reviews

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 100 Publications

20 Customer Reviews

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)